EP0923557A1 - Stereoselective deoxygenation reaction - Google Patents

Stereoselective deoxygenation reaction

Info

Publication number
EP0923557A1
EP0923557A1 EP97937187A EP97937187A EP0923557A1 EP 0923557 A1 EP0923557 A1 EP 0923557A1 EP 97937187 A EP97937187 A EP 97937187A EP 97937187 A EP97937187 A EP 97937187A EP 0923557 A1 EP0923557 A1 EP 0923557A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
group
cycloalkyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97937187A
Other languages
German (de)
French (fr)
Other versions
EP0923557A4 (en
Inventor
Paul N. Devine
Ulf H. Dolling
Lisa F. Frey
Richard D. Tillyer
David M. Tschaen
Yoshiaki Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD KK
Merck and Co Inc
Original Assignee
Banyu Phamaceutical Co Ltd
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9617900.7A external-priority patent/GB9617900D0/en
Priority claimed from GBGB9625806.6A external-priority patent/GB9625806D0/en
Application filed by Banyu Phamaceutical Co Ltd, Merck and Co Inc filed Critical Banyu Phamaceutical Co Ltd
Publication of EP0923557A1 publication Critical patent/EP0923557A1/en
Publication of EP0923557A4 publication Critical patent/EP0923557A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to novel key intermediates in the synthesis of an endothelin antagonist and the method for preparing these key intermediates of formula I.
  • Two endothelin receptor subtypes ETA and ET ⁇ are known so far.
  • the compounds of the present invention possess high affinity to at least one of two receptor subtypes, responsible for the dilation of smooth muscle, such as blood vessels or in the trachea.
  • the endothelin antagonist compounds of the present invention provide a new therapeutic potential, particularly for the treatment of hypertension, pulmonary hypertension, Raynaud's disease, acute renal failure, myocardial infarction, angina pectoris, cerebral infarction, cerebral vasospasm, arteriosclerosis, asthma, gastric ulcer, diabetes, restenosis, prostatauxe endotoxin shock, endotoxin-induced multiple organ failure or disseminated intravascular coagulation, and/or cyclosporin-induced renal failure or hypertension.
  • Endothelin is a polypeptide composed of amino acids, and it is produced by vascular endothelial cells of human or pig. Endothelin has a potent vasoconstrictor effect and a sustained and potent pressor action (Nature, 332, 411-415 (1988)).
  • endothelin isopeptides which resemble one another in structure, exist in the bodies of animals including human, and these peptides have vasoconstriction and pressor effects (Proc. Natl. Acad, Sci, USA, 86. 2863-2867 (1989)).
  • the endothelin levels are clearly elevated in the blood of patients with essential hypertension, acute myocardial infarction, pulmonary hypertension, Raynaud's disease, diabetes or atherosclerosis, or in the washing fluids of the respiratory tract or the blood of patients with asthmaticus as compared with normal levels (Japan, J. Hypertension, 12, 79, (1989), J. Vascular medicine Biology, 2, 207 (1990), Diabetologia, 33, 306-310 (1990), J. Am. Med. Association, 264, 2868 (1990), and The Lancet, ii, 747-748 (1989) and ii, 1144-1147 (1990)).
  • endothelin is secreted not only by endothelial cells but also by tracheal epithelial cells or by kidney cells (FEBS Letters, 255. 129-132 (1989), and FEBS Letters, 249, 42-46 (1989)).
  • Endothelin was also found to control the release of physiologically active endogenous substances such as renin, atrial natriuretic peptide, endothelium-derived relaxing factor (EDRF), thromboxane A2, prostacyclin, noradrenaline, angiotensin II and substance P (Biochem. Biophys, Res. Commun., 157. 1 164-1168 (1988); Biochem. Biophys, Res. Commun., j ⁇ 5, 20 167-172 (1989); Proc. Natl. Acad. Sci. USA, &5_ 1 9797-9800 (1989); J. Cardiovasc. Pharmacol., ⁇ , S89-S92 (1989); Japan. J.
  • endothelin receptors are present in a high density not only in the peripheral tissues but also in the central nervous system, and the cerebral administration of endothelin induces a behavioral change in animals, endothelin is likely to play an important role for controlling nervous functions (Neuroscience Letters, 97, 276- 279 (1989)). Particularly, endothelin is suggested to be one of mediators for pain (Life Sciences, 49, PL61-PL65 (1991)). Internal hyperplastic response was induced by rat carotid artery balloon endothelial denudation. Endothelin causes a significant worsening of the internal hyperplasia (J. Cardiovasc.
  • endothelin is an important mediator for endotoxin- induced diseases (Biochem. Biophys. Commun., 161. 1220-1227 (1989); and Acta Physiol. Scand., 137, 317-318 (1989)).
  • vasoconstriction by the endothelins is caused via at least two subtypes of endothelin receptors (J. Cardiovasc. Pharmacol., 17(Suppl.7). S119-SI21 (1991)).
  • One of the endothelin receptors is ETA receptor Selective to ET-1 rather than ET-3, and the other is ET ⁇ receptor equally active to ET-1 and ET-3. These receptor proteins are reported to be different from each other (Nature, 348. 730- 735 (1990)).
  • endothelin receptors are differently distributed in tissues. It is known that the ETA receptor is present mainly in cardiovascular tissues, whereas the ET ⁇ receptor is widely distributed in various tissues such as brain, kidney, lung, heart and vascular tissues.
  • Substances which specifically inhibit the binding of endothelin to the endothelin receptors are believed to antagonize various pharmacological activities of endothelin and to be useful as a drug in a wide field. Since the action of the endothelins is caused via not only the ETA receptor but also the ET ⁇ receptor, novel non-peptidic substances with ET receptor antagonistic activity to either receptor subtype are desired to block activities of the endothelins effectively in various diseases.
  • Endothelin is an endogenous substance which directly or indirectly (by controlling liberation of various endogenous substances) induces sustained contraction or relaxation of vascular or non-vascular smooth muscles, and its excess production or excess secretion is believed to be one of pathogeneses for hypertension, pulmonary hypertension, Raynaud's disease, bronchial asthma, gastric ulcer, diabetes, arteriosclerosis, restenosis, acute renal failure, myocardial infarction, angina pectoris, cerebral vasospasm and cerebral infarction.
  • endothelin serves as an important mediator involved in diseases such as restenosis, prostatauxe, endotoxin shock, endotoxin- induced multiple organ failure or disseminated intravascular coagulation, and cyclosporin-induced renal failure or hypertension.
  • Two endothelin receptors ETA and ET ⁇ are known so far.
  • An antagonistic agent against the ET ⁇ receptor as well as the ETA receptor is useful as a drug.
  • some non- peptidic compounds possessing antagonistic activity against endothelin receptors were already disclosed in patents (for example, EP 0526708 Al, WO 93/08799 Al). Accordingly, it is an object of the present invention to provide a novel therapeutics for the treatment of the above- mentioned various diseases by an invention of a novel and potent non- peptidic antagonist against either ETA or ET ⁇ receptor.
  • endothelin antagonists of the following structure:
  • Rl is C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, aryl, or heteroaryl;
  • R 4 is C1-C8 alkyl
  • R5 is: H, C1 -C8 alkyl, or aryl.
  • This invention relates to a key intermediate in the synthesis of an endothelin antagonist, the synthesis of this key intermediate and the synthesis of an endothelin antagonist using this intermediate in a stereoselective deoxygenation reaction.
  • the instant invention relates to a compound of formula I:
  • C3-C8 cycloalkyl are unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, Cl -C ⁇ alkoxy, C3-C8 cycloalkyl, CO(CH2) n CH3, and aryl is defined as phenyl or naphthyl, which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, C l -C8 alkoxy, C 1 -C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2) n CH3, CO(CH2)nCH2N(R5)2, and when two substituents are located on adjacent carbons they can join to form
  • n 0 to 5;
  • Rl is: a) C 1 -C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, b) aryl, or c) heteroaryl;
  • heteroaryl is defined as a 5- or 6-membered aromatic ring containing 1 , 2 or 3 heteroatoms selected from O, N and S , which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, C1-C8 alkoxy, Cl-C ⁇ alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, and CO(CH2) n CH2N(R5) 2 ,
  • R 3a is: a) -CO-C1-C8 alkyl, b) -CO-aryl, or c) -CO-heteroaryl;
  • R 3b is: a) C1-C8 alkyl, b) aryl, or c) heteroaryl;
  • R 4 is C1-C8 alkyl
  • R5 is: H, C1-C8 alkyl, or aryl.
  • the instant invention relates to a compound of formula I:
  • C3-C8 cycloalkyl are unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, C1-C8 alkoxy, C3-C8 cycloalkyl, CO(CH2) n CH3, and aryl is defined as phenyl or naphthyl, which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, Cl-C ⁇ alkoxy, Cl-C ⁇ alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2) n CH3, CO(CH2)nCH2N(R5)2, and when two substituents are located on adjacent carbons they can join to form a 5- or 6- member
  • n 0 to 5;
  • Rl is: a) C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, b) aryl, or c) heteroaryl;
  • heteroaryl is defined as a 5- or 6-membered aromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S , which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, Cl-C ⁇ alkoxy, Cl-C ⁇ alkyl, C2-C ⁇ alkenyl, C2-C ⁇ alkynyl, or C3-C ⁇ cycloalkyl, CO(CH2) n CH3, and CO(CH2) n CH2N(R5) 2 ,
  • R 3b is: a) Cl-C ⁇ alkyl, b) aryl, or c) heteroaryl;
  • R 4 is C1-C8 alkyl
  • R5 is: H, C1-C8 alkyl, or aryl.
  • C3-C8 cycloalkyl are unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, Cl-C ⁇ alkoxy, C3-C8 cycloalkyl, CO(CH2) n CH3 , and aryl is defined as phenyl or naphthyl, which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, Cl-C ⁇ alkoxy, C 1 -C ⁇ alkyl, C2-C ⁇ alkenyl, C2-C ⁇ alkynyl, or C3-C8 cycloalkyl, CO(CH2) n CH3, CO(CH2)nCH2N(R 5 )2, and when two substituents are located on adjacent carbons they can join to form
  • n 0 to 5;
  • Rl is: a) Cl-C ⁇ alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C ⁇ cycloalkyl, b) aryl, or c) heteroaryl;
  • heteroaryl is defined as a 5- or 6-membered aromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S , which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, C l -C ⁇ alkoxy, Cl -C ⁇ alkyl, C2-C8 alkenyl, C2-C ⁇ alkynyl, or C3-C cycloalkyl, CO(CH2) n CH3, and CO(CH2) n CH2N(R5) 2 ,
  • R 4 is Cl-C ⁇ alkyl
  • R5 is: H, Cl-C ⁇ alkyl, or aryl
  • the strong base is selected from the group consisting of: LDA, LiHMDS, KHMDS, NaHMDS, KO J Bu, and sodium t-amylate, in about 2 to about 6 equivalents
  • the aprotic solvent is selected from the group consisting of tetrahydrofuran, diethyl ether, MTBE (methyl t-butyl ether), benzene, toluene, pentane, hexane, dioxane and a mixture of said solvents; and the temperature range is about -78°C to about 25°C, and preferably about -50°C to about 25°C.
  • the process conditions for the process recited above are wherein the strong base is LiHMDS, KHMDS, or NaHMDS, preferably in about 3 to about 4 equivalents, the aprotic solvent is tetrahydrofuran and the temperature range is preferably about 0°C to about 25 °C.
  • Cl-Cs alkoxy Cl-C ⁇ alkyl, C2-C alkenyl, C2-C ⁇ alkynyl, or
  • C3-C ⁇ cycloalkyl are unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, C1 -C8 alkoxy, C3-C8 cycloalkyl, CO(CH2) n CH3, and aryl is defined as phenyl or naphthyl, which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, C 1 -C ⁇ alkoxy, C l -C ⁇ alkyl, C2-C ⁇ alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2) n CH3, CO(CH2)nCH2N(R 5 )2, and when two substituents are located on adjacent carbons they can join
  • Rl is: a) C 1 -C ⁇ alkyl, C2-C ⁇ alkenyl, C2-C alkynyl, C3-C cycloalkyl, b) aryl, or c) heteroaryl;
  • heteroaryl is defined as a 5- or 6-membered aromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S , which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, C1-C8 alkoxy, Cl-C ⁇ alkyl, C2-C alkenyl, C2-C ⁇ alkynyl, or C3-C8 cycloalkyl,
  • n 0 to 5;
  • R 4 is Cl-C ⁇ alkyl
  • R5 is: H, Cl-C ⁇ alkyl, or aryl
  • the reducing agent is selected from the group consisting of: a hydride, a borane, C5-C6 cycloalkene with a transition metal catalyst and H2 with a transition metal catalyst.
  • the reducing agents useful in this process in about 2 to about 20 equivalents and preferably about 2 to about 5 equivalents are: hydrides, such as R3S-H, R2SiH2, wherein R is Cl-C ⁇ alkyl or aryl, and NaBH4, boranes, such as BH3 « NHMe2, BH3 » SMe2, BH3 » pyridine, and BH3 » THF, C5-C6 cycloalkene with a transition metal catalyst, such as cyclohexene or cyclohexadiene with Pd/C, Pt-C, Rh/Al and Raney Ni, H2 with a transition metal catalyst, such as Pd-C, Pt-C, Rh/Al and Raney Ni, or S
  • the acid is a Lewis acid
  • the reducing agent when the reducing agent is a hydride, a borane or C5-C6 cycloalkene with a transition metal catalyst, a protic acid, when the reducing agent is H2 with a transition metal catalyst, or no acid, when the reducing agent is Sml2-
  • the Lewis acids in about 2 to about 5 equivalents, such as T-CI4, BF3, BCI3, SnC-4, AICI3, and TiCl2(OiPr)2 are useful in this process.
  • Protic acids such as trifluoroacetic acid, HCl, and H2SO4 are useful in this process.
  • the solvent is an aprotic solvent
  • the acid when the acid is a Lewis acid and the reducing agent is a hydride, a borane or C5-C6 cycloalkene with a transition metal catalyst, a protic solvent, when the acid is a protic acid and the reducing agent is H2 with a transition metal catalyst, or a solvent system consisting of an aprotic solvent and a protic solvent when the reducing agent is Sml2- Aprotic solvents such as tetrahydrofuran, diethyl ether, MTBE (methyl t-butyl ether), dioxane, CH2CI2, CHCI3, nitromethane, toluene, and dichlorobenzene, and protic solvents such as ethanol, methanol or isopropanol, are solvents within the scope of the invention.
  • temperature range is about -78°C to about 20°C and preferably about -20°C to about 10°C, when the acid is a Lewis acid and the reducing agent is a hydride or a borane, about 0°C to about 100°C and preferably about 0°C to about 40°C, when the acid is a Lewis acid or a protic acid and the reducing agent is a C5-C6 cycloalkene with a transition metal catalyst or H2 with a transition metal catalyst, or about 0°C to about 30°C, when the reducing agent is Sml2-
  • the preferred conditions for the process recited above are wherein the hydride is R3SiH, the Lewis acid is TiCl4, the aprotic solvent is nitromethane and the temperature range is about -5°C to about 5°C.
  • alkyl substituents recited above denote straight and branched chain hydrocarbons of the length specified such as methyl, ethyl, isopropyl, isobutyl, tert-butyl, neopentyl, isopentyl, etc.
  • alkenyl-substituents denote alkyl groups as described above which are modified so that each contains a carbon to carbon double bond such as vinyl, allyl and 2-butenyl.
  • alkynyl- substituents denote alkyl groups as described above which are modified so that each contains a carbon to carbon triple bond such as ethynyl,and propynyl.
  • Cycloalkyl denotes rings composed of 3 to 8 methylene groups, each of which may be substituted or unsubstituted with other hydrocarbon substituents, and include for example cyclopropyl, cyclopentyl, cyclohexyl and 4-methylcyclohexyl.
  • the alkoxy substituent represents an alkyl group as described above attached through an oxygen bridge.
  • alkyl, alkenyl, akynyl, cycloalkyl and alkoxy can be substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, Cl-C ⁇ alkoxy, C3-C ⁇ cycloalkyl, CO(CH2) n CH3, and CO(CH2)nCH2N(R5)2.
  • the heteroaryl substituent represents an carbazolyl, furanyl, thienyl, pyrrolyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl, purinyl.
  • the heterocyclyl substituent represents a pyridyl, pyrimidyl, thienyl, furanyl, oxazolidinyl, oxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, imidazolyl, imidazoldinyl, thiazolidilnyl, isoxazolyl, oxadiazolyl, thiadiazolyl, mo ⁇ holinyl, piperidinyl, piperazinyl, pyrrolyl, or pyrrolidinyl.
  • R- 5 chiral auxiliary (R- 5 ), wherein X and Y are independently: O, S, or NR 5 ; R 4 is Cl -Cs alkyl; R5 is: H, Cl -C ⁇ alkyl, or aryl; and R6, R7, R8 and R9 are independently: H, Cl-C ⁇ alkyl, and aryl, such that either R6 and R ⁇ are not the same and/or R& and R9 are not the same, or R6 and R8 or R?
  • R9 can join to form a 5- or 6-membered ring, which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R 4 , Br, Cl, F, I, CF3, N(R5)2, Cl- C8 alkoxy, Cl-C ⁇ alkyl, C2-C ⁇ alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2) n CH3, CO(CH2) n CH2N(R5) 2 .
  • pyridone 1 is alkylated via its dianion with propyl bromide, and the product is then converted into the bromopyridine 3a using a brominating agent such as PBr3.
  • a brominating agent such as PBr3.
  • DIBAL diisobutyl aluminum hydride
  • the aldehyde then undergoes a Heck reaction with t-butyl acrylate using NaOAc, (allyl)2PdCl2, tri-o-tolylphosphine, toluene, reflux to provide the unsaturated ester 4a in high yield.
  • the unsaturated ester 4a is then reacted with a chiral auxiliary to give the acceptor 5a.
  • Examples of chiral auxiliaries useful in this method are the enantiomers of pseudoephedrine, ephedrine, 1 N,2N-dimethyl- diaminocyclohexane, diphenylprolinol, N-methylaminoindanol, and 1 N,2N-diethyldiaminocyclohexane.
  • Organolithium reagent 17a was reacted with the acceptor a (-78°C to -50°C). Workup (acetic acid-THF- water) to remove the chiral auxiliary affords aldehyde 6a in high yield and good selectivity (Scheme 4).
  • the de-oxygenation step can be carried out using a reducing agent including but not limited to trialkylsilyl hydride or samarian iodide, using an acid with the hydride reducing agent.
  • This aldol reaction and de-oxygenation sequence can be carried out with a variety of ketones, such as -COaryl and -COheteraryl.
  • Oxidation of the side chain hydroxyl 21 to the carboxyiic acid 22 was effected using standard conditions (cat RuCl3-NaI ⁇ 4, CH3CN, or two steps involving i) Sulfur trioxide pyridine complex- dimethyl sulfoxide, ii) sodium chlorite-tert butanol). Subsequent hydrolysis (NaOH-MeOH) of 22 provided the target compound 23 cleanly. The iH and 13c NMR spectrum of this material was identical with that of the authentic target compound (Scheme 8).
  • Scheme 9 describes the preparation of the isopropyl ester analog of compound 23 described in Scheme 8.
  • Unsaturated oxazoline 25 was prepared via the Horner-Emmons reaction of phosphonate 24 with the bromopyridine aldehyde 3.
  • Conjugate addition of the lithium anion of 4-bromo-l,2-(methylenedioxy)benzene to 25 produced the desired adduct 26 with in high diastereomeric excess.
  • Hydrolysis of oxazoline 26 was accomplished by refluxing in isopropyl alcohol with concentrated sulfuric acid to yield the isopropyl ester (not shown in scheme).
  • Compound 1 is a commericially available starting material, for example, see Aldrich Chemical Company, Milwaukee, WI, USA 53201.
  • Dissolve 17 (see Example 17, MW 373.41, 2 equ, 14.79 g) in 85 mL THF. Cool to -78°C and add t-BuLi (1.7 M in pentane, 4 equ, 46.6 mL), maintaining temperature below -70°C. Age 15 min, then slowly add solution of 5c (MW 436.59, 19.8 mmol, 8.64 g) in 65 mL THF. Age 1 h at -78°C, then cannula into cold aq NH4CI (100 mL). Add ethyl acetate and separate layers. Wash aqueous with ethyl acetate.
  • Dissolve 17 (see Example 17, MW 373.41, 2 equ, 12.99 g) in 70 mL THF. Cool to -78°C and add t-BuLi (1.7 M in pentane, 4 equ, 40.9 mL), maintaining temperature below -70°C. Age 15 min, then slowly add solution of 5b (MW 384.57, 17.4 mmol, 6.69 g) in 55 mL THF. Age 1 h at -78°C, then cannula into cold aq NH4CI (100 mL). Add ethyl acetate and separate layers. Wash aqueous with ethyl acetate.
  • Compound 7 is a commericially available starting material, for example, see DSM Andeno, Grubbenvorsterweg 8, P.O. Box 81 , 5900 AB Venlo,The Netherlands.
  • Compound 10 is a commericially available starting material, for example, see Lancaster Synthesis, P.O. Box 1000, Windham, NH 03087-9977 or Ryan Scientific, Inc., P.O. Box 845, Isle of Palms, SC 29451-0845.
  • Ar represents:
  • Dissolve 19 (MW 703.99, 13.6 mmol, 9.58 g) in 75 mL THF and cool to -50°C. Slowly add LiHMDS (1.0 M in THF, 5 equ, 68.0 mL) and age 25°C for 16 h. Quench into aqueous NH4CI and add ethyl acetate. Wash organic with brine, dry (magnesium sulfate) and evaporate in vacuo to afford 20 (MW 703.99).
  • Dissolve 20 (MW 703.99, 13.6 mmol) in 125 ml nitromethane and add Et3SiH (MW 1 16.28, d 0.728, 10 equ, 21.7 mL). Cool to 0°C and slowly add TiCl4 (1.0 M in CH2CI2, 4 equ, 54.4 mL) and age 1 h at 0°C. Quench into 2N HCl and dilute with ethyl acetate. Wash aqueous with ethyl acetate, then combine organics and wash with brine. Dry (magnesium sulfate) and evaporate in vacuo.
  • Step B Preparation of 26 51.1 g (215 mmol) of compound 25 from Example 23,
  • Step A were dissolved in IL of THF and cooled to 0° C. 24.7 g (224 mmol) of sodium t-pentoxide was then added. The mixture was aged at 0 - 5° C for about 30 mins. 13.9 mL (224 mmol) of Mel were then added dropwise and the solution allowed to warm to room temperature. After 4 hours, the reaction was quenched with water and extracted with ethylacetate. The organic layer was dried over MgSO/J., filtered and concentrated under reduced pressure to yield 54.04 g (100%) of crude product, 26.
  • Example 17 To a solution of 2.62 g (7.02 mmol) of the arylbromide 17, Example 17 in 15 mL THF was added 3.3 mL (7.1 mmol) of nBuLi (2.15 M in hexanes) while maintaining an internal temperature below -70° C. After 10 minutes, the solution was transferred via cooled cannula (dry ice) to a solution of the diester, 31 produced in Example 27 in 35 mL of THF. The solution was observed to turn a green-black color. The mixture was stirred for an additional 0.5 hours and then quenched with aqueous NaHC ⁇ 3. The aqueous layer was extracted with ethylacetate (2X) and the combined organic layers dried over MgS ⁇ 4.
  • nBuLi 2.15 M in hexanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

This invention relates to a key intermediate in the synthesis of an endothelin antagonist, the synthesis of this key intermediate and the synthesis of an endothelin antagonist using this intermediate in a stereoselective deoxygenation reaction.

Description

TITLE OF THE INVENTION
STEREOSELECTIVE DEOXYGENATION REACTION
BACKGROUND OF THE INVENTION The present invention relates to novel key intermediates in the synthesis of an endothelin antagonist and the method for preparing these key intermediates of formula I.
Two endothelin receptor subtypes ETA and ETβ are known so far. The compounds of the present invention possess high affinity to at least one of two receptor subtypes, responsible for the dilation of smooth muscle, such as blood vessels or in the trachea. The endothelin antagonist compounds of the present invention provide a new therapeutic potential, particularly for the treatment of hypertension, pulmonary hypertension, Raynaud's disease, acute renal failure, myocardial infarction, angina pectoris, cerebral infarction, cerebral vasospasm, arteriosclerosis, asthma, gastric ulcer, diabetes, restenosis, prostatauxe endotoxin shock, endotoxin-induced multiple organ failure or disseminated intravascular coagulation, and/or cyclosporin-induced renal failure or hypertension. Endothelin is a polypeptide composed of amino acids, and it is produced by vascular endothelial cells of human or pig. Endothelin has a potent vasoconstrictor effect and a sustained and potent pressor action (Nature, 332, 411-415 (1988)).
Three endothelin isopeptides (endothelin- 1, endothelin-2 and endothelin-3), which resemble one another in structure, exist in the bodies of animals including human, and these peptides have vasoconstriction and pressor effects (Proc. Natl. Acad, Sci, USA, 86. 2863-2867 (1989)).
As reported, the endothelin levels are clearly elevated in the blood of patients with essential hypertension, acute myocardial infarction, pulmonary hypertension, Raynaud's disease, diabetes or atherosclerosis, or in the washing fluids of the respiratory tract or the blood of patients with asthmaticus as compared with normal levels (Japan, J. Hypertension, 12, 79, (1989), J. Vascular medicine Biology, 2, 207 (1990), Diabetologia, 33, 306-310 (1990), J. Am. Med. Association, 264, 2868 (1990), and The Lancet, ii, 747-748 (1989) and ii, 1144-1147 (1990)).
Further, an increased sensitivity of the cerebral blood vessel to endothelin in an experimental model of cerebral vasospasm (Japan. Soc. Cereb. Blood Flow & Metabol., 1, 73 (1989)), an improved renal function by the endothelin antibody in an acute renal failure model (J. Clin, invest., 8 , 1762-1767 (1989), and inhibition of gastric ulcer development with an endothelin antibody in a gastric ulcer model (Extract of Japanese Society of Experimental Gastric Ulcer, 50 (1991)) have been reported. Therefore, endothelin is assumed to be one of the mediators causing acute renal failure or cerebral vasospasm following subarachnoid hemorrhage.
Further, endothelin is secreted not only by endothelial cells but also by tracheal epithelial cells or by kidney cells (FEBS Letters, 255. 129-132 (1989), and FEBS Letters, 249, 42-46 (1989)).
Endothelin was also found to control the release of physiologically active endogenous substances such as renin, atrial natriuretic peptide, endothelium-derived relaxing factor (EDRF), thromboxane A2, prostacyclin, noradrenaline, angiotensin II and substance P (Biochem. Biophys, Res. Commun., 157. 1 164-1168 (1988); Biochem. Biophys, Res. Commun., j^5, 20 167-172 (1989); Proc. Natl. Acad. Sci. USA, &5_ 1 9797-9800 (1989); J. Cardiovasc. Pharmacol., ϋ, S89-S92 (1989); Japan. J. Hypertension, U, 76 (1989) and Neuroscience Letters, \_Q2, 179-184 (1989)). Further, endothelin causes contraction of the smooth muscle of gastrointestinal tract and the uterine smooth muscle (FEBS Letters, 247, 337-340 (1989); Eur. J. Pharmacol., 154, 227-228 (1988); and Biochem. Biophys Res. Commun., L5J), 317-323 (1989)). Further, endothelin was found to promote proliferation of rat vascular smooth muscle cells, suggesting a possible relevance to the arterial hypertrophy (Atherosclerosis, 78, 225- 228 (1989)). Furthermore, since the endothelin receptors are present in a high density not only in the peripheral tissues but also in the central nervous system, and the cerebral administration of endothelin induces a behavioral change in animals, endothelin is likely to play an important role for controlling nervous functions (Neuroscience Letters, 97, 276- 279 (1989)). Particularly, endothelin is suggested to be one of mediators for pain (Life Sciences, 49, PL61-PL65 (1991)). Internal hyperplastic response was induced by rat carotid artery balloon endothelial denudation. Endothelin causes a significant worsening of the internal hyperplasia (J. Cardiovasc. Pharmacol., 22, 355 - 359 & 371 - 373(1993)). These data support a role of endothelin in the phathogenesis of vascular restenosis. Recently, it has been reported that both ETA and ETβ receptors exist in the human prostate and endothelin produces a potent contraction of it. These results suggest the possibility that endothelin is involved in the pathophysiology of benign prostatic hyperplasia (J. Urology, 151. 763 - 766(1994), Molecular Pharmocol., 45, 306 - 311(1994)). On the other hand, endotoxin is one of potential candidates to promote the release of endothelin. Remarkable elevation of the endothelin levels in the blood or in the culture supernatant of endothelial cells was observed when endotoxin was exogenously administered to animals or added to the culture endothelial cells, respectively. These findings suggest that endothelin is an important mediator for endotoxin- induced diseases (Biochem. Biophys. Commun., 161. 1220-1227 (1989); and Acta Physiol. Scand., 137, 317-318 (1989)).
Further, it was reported that cyclosporin remarkably increased endothelin secretion in the renal cell culture (LLC-PKL cells) (Eur. J. Pharmacol., 180, 191-192 (1990)). Further, dosing of cyclosporin to rats reduced the glomerular filtration rate and increased the blood pressure in association with a remarkable increase in the circulating endothelin level. This cyclosporin-induced renal failure can be suppressed by the administration of endothelin antibody (Kidney Int., 22, 1487-1491 (1990)). Thus, it is assumed that endothelin is significantly involved in the pathogenesis of the cyclosporin-induced diseases. Such various effects of endothelin are caused by the binding of endothelin to endothelin receptors widely distributed in many tissues (Am. J. Physiol., 256, R856-R866 (1989)).
It is known that vasoconstriction by the endothelins is caused via at least two subtypes of endothelin receptors (J. Cardiovasc. Pharmacol., 17(Suppl.7). S119-SI21 (1991)). One of the endothelin receptors is ETA receptor Selective to ET-1 rather than ET-3, and the other is ETβ receptor equally active to ET-1 and ET-3. These receptor proteins are reported to be different from each other (Nature, 348. 730- 735 (1990)).
These two subtypes of endothelin receptors are differently distributed in tissues. It is known that the ETA receptor is present mainly in cardiovascular tissues, whereas the ETβ receptor is widely distributed in various tissues such as brain, kidney, lung, heart and vascular tissues.
Substances which specifically inhibit the binding of endothelin to the endothelin receptors are believed to antagonize various pharmacological activities of endothelin and to be useful as a drug in a wide field. Since the action of the endothelins is caused via not only the ETA receptor but also the ETβ receptor, novel non-peptidic substances with ET receptor antagonistic activity to either receptor subtype are desired to block activities of the endothelins effectively in various diseases.
Endothelin is an endogenous substance which directly or indirectly (by controlling liberation of various endogenous substances) induces sustained contraction or relaxation of vascular or non-vascular smooth muscles, and its excess production or excess secretion is believed to be one of pathogeneses for hypertension, pulmonary hypertension, Raynaud's disease, bronchial asthma, gastric ulcer, diabetes, arteriosclerosis, restenosis, acute renal failure, myocardial infarction, angina pectoris, cerebral vasospasm and cerebral infarction. Further, it is suggested that endothelin serves as an important mediator involved in diseases such as restenosis, prostatauxe, endotoxin shock, endotoxin- induced multiple organ failure or disseminated intravascular coagulation, and cyclosporin-induced renal failure or hypertension. Two endothelin receptors ETA and ETβ are known so far. An antagonistic agent against the ETβ receptor as well as the ETA receptor is useful as a drug. In the field of anti-endothelin agents, some non- peptidic compounds possessing antagonistic activity against endothelin receptors were already disclosed in patents (for example, EP 0526708 Al, WO 93/08799 Al). Accordingly, it is an object of the present invention to provide a novel therapeutics for the treatment of the above- mentioned various diseases by an invention of a novel and potent non- peptidic antagonist against either ETA or ETβ receptor.
In order to accomplish the above object, the present inventors have developed an aldol reaction which enables them to prepare the compound of Formula I,
and use this key intermediate in a stereoselective deoxygenation reaction, also developed by the inventors, to prepare endothelin antagonists of the following structure:
wherein
represents: 5- or 6-membered heterocyclyl, 5- or 6- membered carbocyclyl, and aryl; is aryl, or heteroaryl;
Rl is C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, aryl, or heteroaryl;
R4 is C1-C8 alkyl; and
R5 is: H, C1 -C8 alkyl, or aryl.
SUMMARY OF THE INVENTION
This invention relates to a key intermediate in the synthesis of an endothelin antagonist, the synthesis of this key intermediate and the synthesis of an endothelin antagonist using this intermediate in a stereoselective deoxygenation reaction.
The instant invention relates to a compound of formula I:
wherein
represents:
a) 5- or 6-membered heterocyclyl containing one, two or three double bonds, but at least one double bond and 1, 2 or 3 heteroatoms selected from O, N and S, the heterocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, -C8 alkoxy, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, b) 5- or 6-membered carbocyclyl containing one or two double bonds, but at least one double bond, the carbocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, C1 -C8 alkoxy, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, c) aryl, wherein aryl is as defined below,
C1 -C8 alkoxy, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or
C3-C8 cycloalkyl, are unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl -Cδ alkoxy, C3-C8 cycloalkyl, CO(CH2)nCH3, and aryl is defined as phenyl or naphthyl, which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, C l -C8 alkoxy, C 1 -C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, CO(CH2)nCH2N(R5)2, and when two substituents are located on adjacent carbons they can join to form a 5- or 6- membered ring with one, two or three heteroatoms selected from O, N, and S, which is unsubstituted or substituted with with one, two or three substituents selected from the group consisting of: H, OH, CO2R6, Br, Cl, F, I, CF3, N(R?)2, C1-C8 alkoxy, Cl-Cδ alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, and
n is 0 to 5; Rl is: a) C 1 -C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, b) aryl, or c) heteroaryl;
heteroaryl is defined as a 5- or 6-membered aromatic ring containing 1 , 2 or 3 heteroatoms selected from O, N and S , which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, C1-C8 alkoxy, Cl-Cδ alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2,
R3a is: a) -CO-C1-C8 alkyl, b) -CO-aryl, or c) -CO-heteroaryl;
R3b is: a) C1-C8 alkyl, b) aryl, or c) heteroaryl;
R4 is C1-C8 alkyl; and
R5 is: H, C1-C8 alkyl, or aryl.
Also within the scope of the instant invention is a process preparation of a compound of formula I:
I wherein the substituents are as defined above comprising reacting a
in the presence of a strong base and an aprotic solvent at a temperature range of -78°C to about 25°C.
Also within the scope of the instant invention is a process for the preparation of a compound of formula II:
wherein the substituents are as defined above, comprising reacting a compound of formula I
with a reducing agent and an acid in a solvent at a temperature range of about -78°C to about 100°C.
DETAILED DESCRIPTION OF THE INVENTION
The instant invention relates to a compound of formula I:
wherein
represents:
a) 5- or 6-membered heterocyclyl containing one, two or three double bonds, but at least one double bond and 1 , 2 or 3 heteroatoms selected from O, N and S, the heterocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, C02R4, Br, Cl, F, I, CF3, N(R5)2J C1-C8 alkoxy, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, b) 5- or 6-membered carbocyclyl containing one or two double bonds, but at least one double bond, the carbocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, C1-C8 alkoxy, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, c) aryl, wherein aryl is as defined below, C1-C8 alkoxy, Cl -Cδ alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or
C3-C8 cycloalkyl, are unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, C1-C8 alkoxy, C3-C8 cycloalkyl, CO(CH2)nCH3, and aryl is defined as phenyl or naphthyl, which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, CO(CH2)nCH2N(R5)2, and when two substituents are located on adjacent carbons they can join to form a 5- or 6- membered ring with one, two or three heteroatoms selected from O, N, and S, which is unsubstituted or substituted with with one, two or three substituents selected from the group consisting of: H, OH, CO2R6, Br, Cl, F, I, CF3, N(R?)2, C1-C8 alkoxy, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and
n is 0 to 5;
Rl is: a) C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, b) aryl, or c) heteroaryl;
heteroaryl is defined as a 5- or 6-membered aromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S , which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-Cδ alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2,
R3b is: a) Cl-Cδ alkyl, b) aryl, or c) heteroaryl;
R4 is C1-C8 alkyl; and
R5 is: H, C1-C8 alkyl, or aryl.
An embodiment of the invention is a process for the preparation of a compound of formula I:
wherein
represents:
a) 5- or 6-membered heterocyclyl containing one, two or three double bonds, but at least one double bond and 1 , 2 or 3 heteroatoms selected from O, N and S, the heterocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, C1-C8 alkoxy, Cl-Cδ alkyl, C2-C8 alkenyl, C2-Cδ alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, b) 5- or 6-membered carbocyclyl containing one or two double bonds, but at least one double bond, the carbocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, Cl-Cs alkyl, C2-C8 alkenyl, C2-C alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, c) aryl, wherein aryl is as defined below,
Cl -Cδ alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-C8 alkynyl, or
C3-C8 cycloalkyl, are unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, C3-C8 cycloalkyl, CO(CH2)nCH3 , and aryl is defined as phenyl or naphthyl, which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, C 1 -Cδ alkyl, C2-Cδ alkenyl, C2-Cδ alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, CO(CH2)nCH2N(R5)2, and when two substituents are located on adjacent carbons they can join to form a 5- or 6- membered ring with one, two or three heteroatoms selected from O, N, and S, which is unsubstituted or substituted with with one, two or three substituents selected from the group consisting of: H, OH, CO2R6, Br, Cl, F, I, CF3, N(R?)2, Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-C8 alkenyl, C2-Cδ alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and
n is 0 to 5; Rl is: a) Cl-Cδ alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-Cδ cycloalkyl, b) aryl, or c) heteroaryl;
heteroaryl is defined as a 5- or 6-membered aromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S , which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, C l -Cδ alkoxy, Cl -Cδ alkyl, C2-C8 alkenyl, C2-Cδ alkynyl, or C3-C cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2,
a) -CO-Cl-Cδ alkyl, b) -CO-aryl, or c) -CO-heteroaryl;
a) Cl-Cδ alkyl, b) aryl, or c) heteroaryl;
R4 is Cl-Cδ alkyl; and
R5 is: H, Cl-Cδ alkyl, or aryl,
comprising reacting a
in the presence of a strong base and an aprotic solvent at a temperature range of -78°C to about 25°C.
The process as recited above, wherein the strong base is selected from the group consisting of: LDA, LiHMDS, KHMDS, NaHMDS, KOJBu, and sodium t-amylate, in about 2 to about 6 equivalents; the aprotic solvent is selected from the group consisting of tetrahydrofuran, diethyl ether, MTBE (methyl t-butyl ether), benzene, toluene, pentane, hexane, dioxane and a mixture of said solvents; and the temperature range is about -78°C to about 25°C, and preferably about -50°C to about 25°C.
The process conditions for the process recited above are wherein the strong base is LiHMDS, KHMDS, or NaHMDS, preferably in about 3 to about 4 equivalents, the aprotic solvent is tetrahydrofuran and the temperature range is preferably about 0°C to about 25 °C.
A second embodiment of the invention is a process for the preparation of a compound of formula II:
wherein
represents:
a) 5- or 6-membered heterocyclyl containing one, two or three double bonds, but at least one double bond and 1 , 2 or 3 heteroatoms selected from O, N and S, the heterocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, C1-C8 alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-C alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, b) 5- or 6-membered carbocyclyl containing one or two double bonds, but at least one double bond, the carbocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, C02R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-C alkenyl, C2-C alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, c) aryl, wherein aryl is as defined below,
Cl-Cs alkoxy, Cl-Cδ alkyl, C2-C alkenyl, C2-Cδ alkynyl, or
C3-Cδ cycloalkyl, are unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, C1 -C8 alkoxy, C3-C8 cycloalkyl, CO(CH2)nCH3, and aryl is defined as phenyl or naphthyl, which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, C 1 -Cδ alkoxy, C l -Cδ alkyl, C2-Cδ alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, CO(CH2)nCH2N(R5)2, and when two substituents are located on adjacent carbons they can join to form a 5- or 6- membered ring with one, two or three heteroatoms selected from O, N, and S, which is unsubstituted or substituted with with one, two or three substituents selected from the group consisting of: H, OH, CO2R6, Br, Cl, F, I, CF3, N(R?)2, Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-Cδ alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and
Rl is: a) C 1 -Cδ alkyl, C2-Cδ alkenyl, C2-C alkynyl, C3-C cycloalkyl, b) aryl, or c) heteroaryl;
heteroaryl is defined as a 5- or 6-membered aromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S , which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, C1-C8 alkoxy, Cl-Cδ alkyl, C2-C alkenyl, C2-Cδ alkynyl, or C3-C8 cycloalkyl,
CO(CH2)nCH3, and CO(CH2)nCH2N(R5) ,
n is 0 to 5;
a) C1-C8 alkyl, b) aryl, or c) heteroaryl;
R4 is Cl-Cδ alkyl; and
R5 is: H, Cl-Cδ alkyl, or aryl,
comprising reacting a compound of formula I
with a reducing agent and optionally an acid in a solvent at a temperature range of about -78°C to about 100°C.
The process as recited above, wherein the reducing agent is selected from the group consisting of: a hydride, a borane, C5-C6 cycloalkene with a transition metal catalyst and H2 with a transition metal catalyst. The reducing agents useful in this process in about 2 to about 20 equivalents and preferably about 2 to about 5 equivalents are: hydrides, such as R3S-H, R2SiH2, wherein R is Cl-Cδ alkyl or aryl, and NaBH4, boranes, such as BH3«NHMe2, BH3»SMe2, BH3»pyridine, and BH3»THF, C5-C6 cycloalkene with a transition metal catalyst, such as cyclohexene or cyclohexadiene with Pd/C, Pt-C, Rh/Al and Raney Ni, H2 with a transition metal catalyst, such as Pd-C, Pt-C, Rh/Al and Raney Ni, or Sml2-
The process as recited above, wherein the acid is a Lewis acid, when the reducing agent is a hydride, a borane or C5-C6 cycloalkene with a transition metal catalyst, a protic acid, when the reducing agent is H2 with a transition metal catalyst, or no acid, when the reducing agent is Sml2- The Lewis acids in about 2 to about 5 equivalents, such as T-CI4, BF3, BCI3, SnC-4, AICI3, and TiCl2(OiPr)2 are useful in this process. Protic acids, such as trifluoroacetic acid, HCl, and H2SO4 are useful in this process.
The process as recited above, wherein the solvent is an aprotic solvent, when the acid is a Lewis acid and the reducing agent is a hydride, a borane or C5-C6 cycloalkene with a transition metal catalyst, a protic solvent, when the acid is a protic acid and the reducing agent is H2 with a transition metal catalyst, or a solvent system consisting of an aprotic solvent and a protic solvent when the reducing agent is Sml2- Aprotic solvents such as tetrahydrofuran, diethyl ether, MTBE (methyl t-butyl ether), dioxane, CH2CI2, CHCI3, nitromethane, toluene, and dichlorobenzene, and protic solvents such as ethanol, methanol or isopropanol, are solvents within the scope of the invention.
The process as recited above, wherein temperature range is about -78°C to about 20°C and preferably about -20°C to about 10°C, when the acid is a Lewis acid and the reducing agent is a hydride or a borane, about 0°C to about 100°C and preferably about 0°C to about 40°C, when the acid is a Lewis acid or a protic acid and the reducing agent is a C5-C6 cycloalkene with a transition metal catalyst or H2 with a transition metal catalyst, or about 0°C to about 30°C, when the reducing agent is Sml2-
The preferred conditions for the process recited above are wherein the hydride is R3SiH, the Lewis acid is TiCl4, the aprotic solvent is nitromethane and the temperature range is about -5°C to about 5°C.
The process as recited above for the preparation of a compound of formula:
comprising reacting a ketone of formula:
in tetrahydrofuran with about 3 to about 5 equivalents of lithium bis(trimethylsilyl)amide at about -50°C to about 25°C.
The process as recited above, for the preparation of the compound of formula:
comprising reacting the tertiary alcohol in nitromethane with Et3SiH and TiCl4 at about -5°C to about 5°C.
The process as recited above, for the preparation of the compound of formula:
comprising reacting the tertiary alcohol
OMe in a solution of isopropyl alcohol and tetrahydrofuran with Sml2 at about 10° - 30°C.
The process as recited above, for the preparation of the compound of formula:
comprising reacting the tertiary alcohol in a solution of isopropyl alcohol and tetrahydrofuran with Sml2 at about 10° - 30°C.
It is further understood that the substituents recited above would include the definitions recited below.
The alkyl substituents recited above denote straight and branched chain hydrocarbons of the length specified such as methyl, ethyl, isopropyl, isobutyl, tert-butyl, neopentyl, isopentyl, etc.
The alkenyl-substituents denote alkyl groups as described above which are modified so that each contains a carbon to carbon double bond such as vinyl, allyl and 2-butenyl.
The alkynyl- substituents denote alkyl groups as described above which are modified so that each contains a carbon to carbon triple bond such as ethynyl,and propynyl. Cycloalkyl denotes rings composed of 3 to 8 methylene groups, each of which may be substituted or unsubstituted with other hydrocarbon substituents, and include for example cyclopropyl, cyclopentyl, cyclohexyl and 4-methylcyclohexyl.
The alkoxy substituent represents an alkyl group as described above attached through an oxygen bridge.
Additionally, it is understood that the terms alkyl, alkenyl, akynyl, cycloalkyl and alkoxy can be substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, C3-Cδ cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2.
The heteroaryl substituent represents an carbazolyl, furanyl, thienyl, pyrrolyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl, purinyl.
The heterocyclyl substituent represents a pyridyl, pyrimidyl, thienyl, furanyl, oxazolidinyl, oxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, imidazolyl, imidazoldinyl, thiazolidilnyl, isoxazolyl, oxadiazolyl, thiadiazolyl, moφholinyl, piperidinyl, piperazinyl, pyrrolyl, or pyrrolidinyl.
The α,β-unsaturated ester or amide
can generally be prepared in two steps:
1 ) a coupling reaction at the one position of Ring A
wherein Z is a leaving such as Br, Cl, I, OTriflyl, OTosyl or OMesyl and R2 is OR4 or N(R5)2; and 2) the conversion of the aldehyde (R3a= CHO) to the desired
chiral auxiliary (R-5), wherein X and Y are independently: O, S, or NR5; R4 is Cl -Cs alkyl; R5 is: H, Cl -Cδ alkyl, or aryl; and R6, R7, R8 and R9 are independently: H, Cl-Cδ alkyl, and aryl, such that either R6 and R^ are not the same and/or R& and R9 are not the same, or R6 and R8 or R? and R9 can join to form a 5- or 6-membered ring, which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl- C8 alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, CO(CH2)nCH2N(R5)2.
Commercially available pyridone 1 is alkylated via its dianion with propyl bromide, and the product is then converted into the bromopyridine 3a using a brominating agent such as PBr3. The nitrile
3a is then reduced to the aldehyde 3 using diisobutyl aluminum hydride (DIBAL). The aldehyde then undergoes a Heck reaction with t-butyl acrylate using NaOAc, (allyl)2PdCl2, tri-o-tolylphosphine, toluene, reflux to provide the unsaturated ester 4a in high yield. The unsaturated ester 4a is then reacted with a chiral auxiliary to give the acceptor 5a. Examples of chiral auxiliaries useful in this method are the enantiomers of pseudoephedrine, ephedrine, 1 N,2N-dimethyl- diaminocyclohexane, diphenylprolinol, N-methylaminoindanol, and 1 N,2N-diethyldiaminocyclohexane.
SCHEME 1
3a
chiral . auxiliary
Commericially available acid 10 is reduced with BH3#SMe2, to the alcohol 11, which is then converted into the bromidel3, via the mesylate 12 using mesyl chloride, triethylamine followed by the addition of NaBr and dimethyl acetamide (DMAC).
SCHEME 2
Commercial available 1 ,2-amino indanol is acylated (propionyl choride, K2CO3) to give amide 8, which is then converted into the acetonide 9 (2-methoxypropene, pyridinium p-toluene-sulfonate (PPTS)). Acetonide 9 is then alkylated with the bromide 13, (LiHMDS) to give 14, which is then hydrolyzed (H+, MeOH) to give a mixture of acid and methyl ester 15. Reduction (LAH) of the ester/acid mixture provided the alcohol 16 in high yield and optical purity. Protection of the alcohol 16 (TBSC1, imidazole) provided bromide 17, the precursor to organolithium 17a. SCHEME 3
14
Organolithium reagent 17a was reacted with the acceptor a (-78°C to -50°C). Workup (acetic acid-THF- water) to remove the chiral auxiliary affords aldehyde 6a in high yield and good selectivity (Scheme 4).
SCHEME 4
Attempts were made to close the five membered ring via intramolecular alkylation chemistry (Scheme 5). Thus the aldehyde 6a was converted into a 1 : 1 mixture of chlorides 25 (Grignard addition, then MsCl) which were then reacted with LDA (-78°C) to give cleanly a 60:40 mixture of 21c and 21a.
SCHEME 5
The low stereoselectivity of this alkylation reaction prompted us to develop an alternative ring closure strategy, involving an aldol and stereoselective de-oxygenation sequence (Scheme 6 and Scheme 7). The aldehyde 6a was converted into the keto ester 19 in two steps (85%), involving Grignard addition to give the alcohol 18, followed by oxidation with TPAP. Finally, transesterification of the t-butyl ester (n-BuOH, Ti(OBu)4) provides the n-butyl ester 19 quantitatively (Scheme 6). SCHEME 6
19 undergoes an aldol reaction (LiHMDS, THF, 25°C) to provide two tertiary alcohols 20 (1: 1), which were de-oxygenated cleanly to give the desired heterocycle 21 in excellent yield (75% for three steps). The selectivity in this reaction was estimated by AH NMR to be >90% de (Scheme 7). The de-oxygenation step can be carried out using a reducing agent including but not limited to trialkylsilyl hydride or samarian iodide, using an acid with the hydride reducing agent. This aldol reaction and de-oxygenation sequence can be carried out with a variety of ketones, such as -COaryl and -COheteraryl.
SCHEME 7
Oxidation of the side chain hydroxyl 21 to the carboxyiic acid 22 was effected using standard conditions (cat RuCl3-NaIθ4, CH3CN, or two steps involving i) Sulfur trioxide pyridine complex- dimethyl sulfoxide, ii) sodium chlorite-tert butanol). Subsequent hydrolysis (NaOH-MeOH) of 22 provided the target compound 23 cleanly. The iH and 13c NMR spectrum of this material was identical with that of the authentic target compound (Scheme 8).
SCHEME 8
Scheme 9 describes the preparation of the isopropyl ester analog of compound 23 described in Scheme 8. Unsaturated oxazoline 25 was prepared via the Horner-Emmons reaction of phosphonate 24 with the bromopyridine aldehyde 3. Conjugate addition of the lithium anion of 4-bromo-l,2-(methylenedioxy)benzene to 25 produced the desired adduct 26 with in high diastereomeric excess. Hydrolysis of oxazoline 26 was accomplished by refluxing in isopropyl alcohol with concentrated sulfuric acid to yield the isopropyl ester (not shown in scheme).
Subsequent carbonylation of the isopropyl ester using catalytic palladium in methanol produced diester 27. Inverse addition of the lithium anion of 17 to methyl ester 27 at - 7δ° C generated the desired ketoester 28. Compound 28 was then treated with aqueous HF to remove the silyl protecting group. The deprotected alcohol was then cyclized with sodium t-amylate to form the aldol adduct 29. Finally, aldol adduct 29 was oxidized to the carboxyiic acid, and then stereoselectively deoxygenated by the action of Sml2 to produce 30 as a single diastereomer.
SCHEME 9
nBuϋ, THF
nBuLi, THF 27 SCHEME 9 (continued)
The instant invention can be understood further by the following examples, which do not constitute a limitation of the invention. Note that the reference numbers utilized in the examples below do not necessarily correspond with the reference numbers utilized in the Schemes.
EXAMPLE 1
Preparation of 1
Compound 1 is a commericially available starting material, for example, see Aldrich Chemical Company, Milwaukee, WI, USA 53201.
EXAMPLE 2
Preparation of 2 Diisopropyl amine (MW 101.19, d 0.772, 2.1 equ, 20.54 mL) in 200 mL THF. Cool to -50°C and add n-BuLi (1.6 M in hexanes, 2.05 equ, 96 mL), allowing solution to warm to -20°C. Age 0-3°C for 15 min, then cool to -30°C and add 1 (MW 134.14, 75 mmol, 10.0 g). Age 0°C to 43°C for 2 h. Cool to -50°C and add bromopropane (MW 123.00, d 1.354, 1.0 equ, 6.8 mL). Warm to 25°C over 30 min, and age 30 min. Add NH4CI and CH2CI2. Dry organic (magnesium sulfate) then evaporate in vacuo to afford 61% of 2.
EXAMPLE 3
Preparation of 3
Mix 2 (MW 176.22, 46 mmol) and PBr3 (MW 270.70, d 2.880, 2.5 equ, 10.8 mL) and age at 160°C. After 2 h, cool to 25°C and add some CH2O2. Slowly quench by adding water. Separate layers and wash aqueous two times with CH2C12- Combine organic layers and dry (magnesium sulfate). Concentrate and isolate solid by silica gel chromatography (90: 10 hexanes:ethyl acetate) in 60% yield (MW 239.12, 6.60 g).
Dissolve product of bromination reaction (MW 239.12, 27.6 mmol, 6.60 g) in 66 mL toluene and cool to - 2°C. Slowly add DIBAL (1.5 M in toluene, 2 equ, 37 mL) and age 1 h at -42°C. Add HCl (2 N, 10 equ, 134 mL) and stir vigorously for 30 min. Dilute with ethyl acetate, separate layers, and wash aqueous with ethyl acetate. Combine organic layers, dry (magnesium sulfate), and concentrate in vacuo to afford 90% (MW 242.11, 6.01 g) of 3. EXAMPLE 4a
Preparation of 4a
Dissolve 3 (MW 242.1 1, 24.δ mmol, 6.01 g) in 75 mL toluene. Add sodium acetate (MW 82, 3 equ, 6.13 g), t-butyl acrylate (MW 128.17, d 0.875, 2.5 equ, 9.08 mL), P(o-tolyl)3 (MW 304.38, 10 mol %, 755 mg) and allyl palladium chloride dimer (MW 365.85, 5 mol %, 455 mg). Age at reflux for 24 h. Cool, filter and evaporate in vacuo. Isolate 4a (MW 289.37) by silica gel chromatography (92:δ hexanes: ethyl acetate) in δ0% yield (5.74 g).
EXAMPLE 4b
Preparation of 4 b
Dissolve 3 (MW 242.11, 24.δ mmol, 6.01 g) in 75 mL toluene. Add sodium acetate (MW 82, 3 equ, 6.13 g), dimethylacrylamide (MW 99.13, d 0.962, 1 equ, 2.55 mL), PPI13 (MW 262.29, 10 mol %, 653 mg) and allyl palladium chloride dimer (MW 365.85, 5 mol %, 455 mg). Age at 140°C in sealed tube for 24 h. Cool, filter and evaporate in vacuo. Isolate 4b (MW 260.34) by silica gel chromatography (80:20 hexanes:ethyl acetate) in 70% yield (4.52 g). EXAMPLE 5a
Preparation of 5a
Dissolve 4a (MW 289.37, 19.8 mmol, 5.74 g) in 53 mL CH2C12- Add (lR,2R)-N,N-dimethylcyclohexanediamine (MW 142.24, 1 equ, 2.83 g) and sieves (powdered, 1 wt equ, 5.74 g) and age 25 °C for 8 h. Filter and concentrate filtrate in vacuo to afford 5a (MW 413.60, 8.19 g) in quantitative yield.
EXAMPLE 5b
Preparation of 5b
Dissolve 4b (MW 260.34, 17.4 mmol, 4.53 g) in 40 mL CH2O2. Add (lR,2R)-N,N-dimethylcyclohexanediamine (MW 142.24, 1 equ, 2.47 g) and sieves (powdered, 1 wt equ, 4.53 g) and age 25°C for 8 h. Filter and concentrate filtrate in vacuo to afford 5b (MW 384.57, 6.69 g) in quantitative yield. EXAMPLE 5c
Preparation of 5c
Dissolve 4a (MW 289.37, 19.8 mmol, 5.74 g) in 53 mL toluene. Add (S,S)-pseudoephedrine (MW 165.24, 1.1 equ, 3.60 g) and 4 drops of concentrated HCl. Reflux with a Dean-Stark trap for 2h. Wash with saturated aqueous NaHCθ3 and extract with ethyl acetate. Dry organic layer with MgSθ4, then filter and concentrate filtrate in vacuo to afford 5c (MW 4436.59, 8.64 g) in quantitative yield. lH NMR (CDC13) : 8.23 (d, 7=11.78, 1 H), 7.88 (d, 7=7.33, 1 H), 7.39 (m, 5 H), 7.16 (d, 7=7.33, 1 H), 7.02 (d, 7=11.78, 1 H), 5.31 (s, 1 H), 4.80 (d, 7=9.18, 1 H), 2.80 (t, 7=5.79, 2 H), 2.59 (m, 1 H), 2.19 (s, 3 H), 1.72 (m, 2 H), 1.56 (s, 9 H), 1.39 (m, 2 H), 1.27 (d, 7=4.83, 3 H), 0.94 (t, 7=6.76, 3 H).
EXAMPLE 5d
Preparation of 5d Dissolve 4b (MW 260.34, 117.4 mmol, 5.74 g) in 53 mL toluene. Add (S,S)-pseudoephedrine (MW 165.24, 1.1 equ, 3.16 g) and 4 drops of concentrated HCl. Reflux with a Dean-Stark trap for 2h. Wash with saturated aqueous NaHC03 and extract with ethyl acetate. Dry organic layer with MgSθ4, then filter and concentrate filtrate in vacuo to afford 5c.
EXAMPLE 6a
Preparation of 6a
Dissolve 17 (see Example 17, MW 373.41, 2 equ, 14.79 g) in 85 mL THF. Cool to -78°C and add t-BuLi (1.7 M in pentane, 4 equ, 46.6 mL), maintaining temperature below -70°C. Age 15 min, then slowly add solution of 5c (MW 436.59, 19.8 mmol, 8.64 g) in 65 mL THF. Age 1 h at -78°C, then cannula into cold aq NH4CI (100 mL). Add ethyl acetate and separate layers. Wash aqueous with ethyl acetate. Combine organic layers and wash with brine, then dry (magnesium sulfate) and evaporate in vacuo. 1 H NMR provides de data. Add THF (75 mL), acetic acid (AcOH) (30 mL) and water (10 mL). Age 5 h at 25°C. Separate layers and wash aqueous two times with ethyl acetate. Combine organic layers, wash with brine, dry (magnesium sulfate), and evaporate in vacuo. 6a (MW 583.89) is isolated in 85% yield (9.83 g) by silica gel chromatography (92:8 hexanes :ethyl acetate). lH NMR (C6D6) : 10.5 (s, 1 H), 7.72 (d, 7=7.85, 1 H), 7.30 (d, 7=8.64, 1 H), 6.83 (d, 7=8.05, 1 H), 6.59 (dd, 7=8.65, 2.61, 1 H), 6.56 (d, 7=7.99, 1 H), 5.92 (m, 1 H), 3.85 (dd, 7=16.32, 10.77, 1 H), 3.4δ (m, 2 H), 3.32 (s, 3 H), 3.01 (dd, 7=14.11, 6.77, 1 H), 2.87 (dd, 7=16.30, 3.91, 1 H), 2.79 (dd, 7=13.25, 6.21 , 1 H), 2.68 (t, 7=7.66, 2 H), 2.10 (m, 1 H), 1.72 (m, 2 H), 1.30 (s, 9 H), 1.25 (m, 2 H), 1.01 (s, 9 H), 0.95 (d, 7=6.42, 3 H), 0.94 (t, 7=8.40, 3 H), 0.10 (d, 7=5.83, 6 H).
EXAMPLE 6b
Preparation of 6 b
Dissolve 17 (see Example 17, MW 373.41, 2 equ, 12.99 g) in 70 mL THF. Cool to -78°C and add t-BuLi (1.7 M in pentane, 4 equ, 40.9 mL), maintaining temperature below -70°C. Age 15 min, then slowly add solution of 5b (MW 384.57, 17.4 mmol, 6.69 g) in 55 mL THF. Age 1 h at -78°C, then cannula into cold aq NH4CI (100 mL). Add ethyl acetate and separate layers. Wash aqueous with ethyl acetate. Combine organic layers and wash with brine, then dry (magnesium sulfate) and evaporate in vacuo. 1 H NMR provides de data. Add THF (55 mL), AcOH (20 mL) and water (8 mL). Age 5 h at 25°C. Separate layers and wash aqueous two times with ethyl acetate. Combine organic layers, wash with brine, dry (magnesium sulfate), and evaporate in vacuo. 6b (MW 678.99) is isolated in 75% yield (8.86 g) by silica gel chromatography (70:30 hexanes:ethyl acetate). lH NMR (CDCI3) : 10.30 (s, 1 H), 7.99 (d, 7=4.74, 1 H), 7.11 (d, 7=3.19, 1 H), 6.89 (d, 7=8.61, 1 H), 6.78 (d, 7=2.76, 1 H), 6.59 (t, 7=2.78, 1 H), 5.70 (t, 7=2.86, 1 H), 3.87 (dd, 7=11.18, 4.29, 1 H), 3.74 (s, 3 H), 3.58 (m, 2 H), 3.11 (s, 3 H), 3.25 (dd, 7=14.35, 6.25, 1 H), 2.88 (s, 3 H), 2.84 (m, 2H), 2.68 (dd, 7=14.35, 8.30, 1 H), 2.47 (dd, 7=9.02, 2.89, 1 H), 2.09 (m, 1 H), 1.75 (m, 2 H), 1.39 (m, 2 H), 0.99 (t, 7=3.49, 3 H), 0.92 (s, 9 H), 0.92 (d, 7=7.15, 6 H), 0.08 (d, 7=1.91, 6 H).
13c NMR (CDCI3) : 190.5, 171.6, 165.9, 163.7, 157.9, 139.3, 137.2, 135.5, 130.0, 127.1, 120.8, 115.5, 111.7, 67.8, 55.11, 39.7, 38.9, 38.4, 37.2, 36.8, 36.0, 35.4, 26.0 (3 C), 22.3, 18.4, 17.3, 14.7, -5.3 (2 C).
EXAMPLE 7
Preparation of 7
Compound 7 is a commericially available starting material, for example, see DSM Andeno, Grubbenvorsterweg 8, P.O. Box 81 , 5900 AB Venlo,The Netherlands.
EXAMPLE 8
8
Preparation of 8
Na2Cθ3 (MW 105.99, 1.5 equ, 8.8 g) dissolved in 82 mL water. Add a solution of (1R,2S) aminoindanol 7 (MW 149.19, 55.0 mmol, 8.2 g) in 160 mL CH2CI2. Cool to -5°C and add propionyl chloride (MW 92.53, d 1.065, 1.3 equ, 6.2 mL). Warm to 25°C and age 1 h. Separate layers and dry organic (magnesium sulfate). Concentrate in vacuo to afford 8 (MW 205.26, 10 g) in 89% isolated yield. EXAMPLE 9
8
Preparation of 9
To a solution of 8 (MW 205.26, 49.3 mmol, 10 g) in 200 mL THF, add pyridinium /?-toluenesulfonate (PPTS) (MW 251.31 , 0.16 equ, 2g) then methoxypropene (MW 72.11 , d 0.753, 2.2 equ, 10.4 mL). Age 2 h at 38°C, then add aqueous sodium bicarbonate and ethyl acetate. The organic layer was dried (magnesium sulfate). After concentration in vacuo, 9 (MW 245.32, 12.09 g) was formed in quantitative yield.
EXAMPLE 10
10
Preparation of 10
Compound 10 is a commericially available starting material, for example, see Lancaster Synthesis, P.O. Box 1000, Windham, NH 03087-9977 or Ryan Scientific, Inc., P.O. Box 845, Isle of Palms, SC 29451-0845. EXAMPLE 1 1
Preparation of 11
10 (MW 231.05, 130 mmol, 30.0 g) in 300 mL CH2CI2 at 0°C. Add BH3-SMe2 (3 equ, 25.2 mL) and age for 2 h at 25°C. Quench into aqueous 2 N HCl and separate layers. Dry organic (magnesium sulfate) and concentrate in vacuo to obtain 94% yield of 11 (MW 217.06, 25.5 g).
EXAMPLE 12
Preparation of 12
Dissolve 11 (MW 217.06, 47.2 mmol, 10.24 g) in 55 mL CH2CI2 and cool to -20°C. Add DIEA (MW 129.25, d 0.742, 1.3 equ, 10.69 mL) then methane sulfonyl chloride (MsCl) (MW 1 14.55, d 1.480, 1.2 equ, 4.38 mL). Age -5°C to 0°C for 1 h then quench into 55 mL water. Extract with CH2CI2 then wash with IN H2SO4 (40 mL), then brine. Dry organic layers (magnesium sulfate) and concentrate in vacuo to afford 12 (MW 295.15, 13.23 g) in 95% yield. EX AMPLE 13
Preparation of 13
12 (MW 295.15, 44.8 mmol, 13.23 g) in 44 mL dimethylacetamide (DMAC). Add NaBr (MW 102.90, 2 equ, 9.22 g) and age lh. Add 88 mL water and collect solid by filtration. Wash cake with water and dry by suction. Quantitative yield of 13 (MW 279.96, 12.54 g) is obtained.
EXAMPLE 14
Preparation of 14
9 (MW 245.32, 1.1 equ, 89.1 g) in 1 L THF, cooled to -50°C. Add lithium bis(trimethylsilyl)amide (LiHMDS) (1.0 M in THF, 1.5 equ, 545 mL) and age 1.5 h, warming to -30°C. Add 13 (MW 279.96, 327 mmol, 91.3 g) in 300 mL THF, and age -35°C for 1 h. Warm to -10°C over 1 h, then quench into aqueous NH4CI. Separate layers and extract with ethyl acetate. Dry organic and concentrate in vacuo to afford crude 14 (MW 444.37).
EXAMPLE 15
Preparation of 15
14 in 1 L MeOH and cooled to 10°C. Bubble in HCl gas for 1 h until reaction is complete. 2 L H2θ added and the product was filtered. The cake was washed with H2θ and dried to give the product hydroxyamide, which was then dissolved in 1 L MeOH and 1.5 L 6N HCl and refluxed overnight. The mixture was cooled to 25°C and extracted with CH2CI2 to give, after concentration, compounds 15 (60 g, 64% from bromide 13).
EXAMPLE 16
15 16
Preparation of 16
15 (mixture of acid and ester, 26.88 mmol) in 150 mL THF at -78°C. Add lithium aluminum hydride (LiAlH4) (1 M in THF, 2 equ, 53.76 mL) over 30 min. Warm to 25°C over 1 h, then quench into aqueous NH4CI. Add ethyl acetate, extract ethyl acetate. Wash organics with brine, dry (magnesium sulfate), and concentrate in vacuo to afford 95% yield of 16 (MW 259.14, 6.62 g).
EXAMPLE 17
Preparation of 17
16 (MW 259.14, 25.54 mmol, 6.62 g) in 35 mL CH2CI2 and cool to 0°C. Add imidazole (MW 68.08, 2.5 equ, 4.35 g) and then tert-butyldimethylsilyl chloride (TBSC1) (MW 150.73, 1 equ, 3.85 g). Age 1 h at 25 °C then quench with aqueous NaHCθ3 and add ethyl acetate. Extract with ethyl acetate, then dry organic layer (magnesium sulfate) and concentrate in vacuo to afford a quantitative yield of 17 (MW 373.41, 9.54 g). iH NMR (CDCI3) : 7.41 (d, 7=8.74, 1H), 6.77 (d, 7=3.04, 1H), 6.63 (dd, 7=8.73, 3.06, IH), 3.78 (s, 3 H), 3.50 (d, 7=5.75, 2 H), 2.89 (dd, 7=13.31, 6.15, 1 H), 2.45 (dd, 7=13.30, 8.26, 1 H), 2.03 (m, 1 H), 0.94 (s, 9 H), 0.92 (d, 7=5.01, 3 H), 0.07 (s, 6 H).
13c NMR (CDCI3) : 159.1 , 141.6, 133.2, 117.0, 1 15.4, 113.2, 67.4, 55.4, 39.7, 36.3, 26.0 (3C), 18.4, 16.5, -5.3 (2C). EXAMPLE 18
Ar represents:
OMe
Preparation of 18
Prepare 0.5 M Grignard solution from 4-bromo-l,2- (methylenedioxy)benzene (MW 201.01, 42.1 mmol, 8.46 g) and Mg (MW 24.31, 1.5 equ, 1.54 g) in 84 mL THF. Dissolve 6a (MW 583.89, 16.8 mmol, 9.83 g) in 80 mL THF and cool to -78°C. Slowly add Grignard solution (2.5 equ, 0.5 M, 84 mL) and age 30 min. Quench into aqueous NH4CI and add ethyl acetate. Wash organic with brine, dry (magnesium sulfate) and evaporate in vacuo. Carry crude into oxidation. EXAMPLE 19
Preparation of 19
Crude 18 (MW 706.01, 16.8 mmol) in 150 mL ACN. Add NMO (MW 117.15, 3 equ, 5.90 g), sieves (powdered, 3 wt equ, 35.6 g), and TPAP (MW 351.43, 10 mol %, 590 mg) and age 25°C for 2 h. Concentrate to remove ACN, then elute through silica gel pad with ethyl acetate. Concentrate in vacuo, then chromatograph (90:10 hexanes:ethyl acetate) to isolate the oxidation product (85% yield over two steps).
Dissolve in 100 mL n-BuOH and add Ti(OBu)4 (MW 340.366, 5 equ, 28.59 g). Reflux for 48 h, then quench into water and add ethyl acetate. Filter through celite, separate the layers, and wash the organic with brine. Dry (magnesium sulfate) and evaporate in vacuo to afford 81% yield (over three steps) of 19 (MW 703.99, 9.58 g).
EXAMPLE 20
Preparation of 20
Dissolve 19 (MW 703.99, 13.6 mmol, 9.58 g) in 75 mL THF and cool to -50°C. Slowly add LiHMDS (1.0 M in THF, 5 equ, 68.0 mL) and age 25°C for 16 h. Quench into aqueous NH4CI and add ethyl acetate. Wash organic with brine, dry (magnesium sulfate) and evaporate in vacuo to afford 20 (MW 703.99).
EXAMPLE 21
Preparation of 21
Dissolve 20 (MW 703.99, 13.6 mmol) in 125 ml nitromethane and add Et3SiH (MW 1 16.28, d 0.728, 10 equ, 21.7 mL). Cool to 0°C and slowly add TiCl4 (1.0 M in CH2CI2, 4 equ, 54.4 mL) and age 1 h at 0°C. Quench into 2N HCl and dilute with ethyl acetate. Wash aqueous with ethyl acetate, then combine organics and wash with brine. Dry (magnesium sulfate) and evaporate in vacuo. Isolate by silica gel chromatography (75:25 hexanes:ethyl acetate) to afford a 75% yield (over two steps) of 21 (MW 573.73, 5.85 g). H NMR (CDCI3) : 7.20 (d, 7=7.80, 1 H), 6.95 (d, 7=7.83, 1 H), 6.88 (d, 7=8.37, 1 H), 6.76 (m, 5 H), 5.95 (s, 2 H), 5.04 (d, 7=9.86, 1 H), 4.53 (d, 7=9.67, 1 H), 4.02 (m, 2 H), 3.78 (s, 3 H), 3.55 (m, 1 H), 3.45 (m, 1 H), 3.34 (, 7=9.82, 1 H), 2.66 (m, 2 H), 2.58 (m, 2 H), 2.14 (m, 1 H), 1.56 (m, 2 H), 1.44 (m, 2 H), 1.28 (m, 2 H), 1.11 (m, 2 H), 1.01 (d, 7=6.77, 3 H), 0.86 (t, 7=7.26, 3 H), 0.81 (t, 7=7.37, 3 H). 13c NMR (CDCI3) : 174.1, 164.3, 162.8, 157.8, 148.1 , 146.8, 141.6, 136.3, 135.0, 133.1, 132.4, 129.6, 121.8, 121.2, 1 15.5, 1 12.3, 108.4, 101.1, 67.4, 64.8, 63.6, 60.4, 55.1 , 51.5, 38.8, 37.6, 37.4, 32.3, 30.6, 22.3, 18.9, 18.0, 14.2, 14.0, 13.6.
EXAMPLE 22
16 22
Preparation of 22 To a suspension of 60% NaH (1.25 equ, 7.7 lg) in THF (450 ml) and DMF (10 ml) was added dropwise a solution of 16 (MW 259.14, 154 mmol, 40.0 g) (Compound 16 was prepared according to the procedure of described in Example 16) in THF (200 ml) below 10°C. Benzylchloride (MW 126.59, 1.1 equ, 21.4 g) was added to the mixture and the mixture was refluxed for 4 h, cooled to room temperature, poured into ice water (500 ml), and extracted with ethyl acetate (1 L). The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with dil. HCl, sat. aqueous NaHC03, water then brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo. 22 (MW 349.27) was isolated in 98% yield (52.8g) by silica gel chromatography (heptane-ethyl acetate / gradient). iH NMR (CDC13): 0.96 (d, J=6.60, 3H), 2.20 (m, IH), 2.70 (m, 2H), 3.37 (m, 2H), 3.73 (s, 3H), 4.52 (s, 2H), 6.63 (dd, J=2.97, 8.91, IH), 6.75 (d, J=2.97, IH), 7.37 (m, 5H), 7.41 (d, J=8.91 , IH).
EXAMPLE 23
27
Preparation of 27
Step A: Preparation of 25
100 g (0.81 mols) of ethylacetimidate hydrochloride, 23 and 173 g (0.81 mols) of (S,S)-thiomicamine, 24 were combined in 1 L of CH2CI2 and stirred at room temperature overnight. The reaction was then quenched with water and extracted with CH2CI2. The organic phase was dried over MgSθ4, filtered, and concentrated under reduced pressure. Recrystallization was accomplished using 700 mL of hot acetonitrile. Crystallization began at about 40° C. The solution was cooled to room temperature (about 20° C) then cooled to 15° C. The resulting crystals were collected by vaccum filtration and air-dried over night to afford 134.5 g (70%) of the product, compound 25.
Step B: Preparation of 26 51.1 g (215 mmol) of compound 25 from Example 23,
Step A were dissolved in IL of THF and cooled to 0° C. 24.7 g (224 mmol) of sodium t-pentoxide was then added. The mixture was aged at 0 - 5° C for about 30 mins. 13.9 mL (224 mmol) of Mel were then added dropwise and the solution allowed to warm to room temperature. After 4 hours, the reaction was quenched with water and extracted with ethylacetate. The organic layer was dried over MgSO/J., filtered and concentrated under reduced pressure to yield 54.04 g (100%) of crude product, 26.
Step C: Preparation of 27
132 mL (946 mmol) of diisopropylamine were dissolved in 200 mL THF and cooled to - 21 ° C. 420 mL (946 mmol) of nBuLi (2.25 M in hexanes) were then added. The mixture was aged at -30 to -45° C for about 40 minutes. The mixture was then cooled to -78° C and 108 g (430 mmol) of the product, 26 from Example 23, Step B in 200 mL of THF were added dropwise while maintaining an internal temperature of about -70° C. After an additional 40 minutes, 66.5 mL (460.1 mmol) of diethylchlorophosphate were added neat. The solution was then allowed to warm to -10° C, quenched with water, and extracted with ethylacetate. The organic layer was dried over MgSθ4, filtered, and concentrated under reduced pressure to yield 166.1 1 g (99%) of the crude product, 27.
EXAMPLE 24
Preparation of 28
83.3 g (215 mmol) of the product, compound 27 from Example 23, Step C were dissolved in IL THF and cooled to -15° C. 90.3 mL (226 mmol) of nBuLi (2.5 M in hexanes) were then added dropwise while maintaining an internal temperature under 0° C. After 15 minutes, 41.6 g (172 mmol) of 2-bromo-6-butyl-3-pyridine- carboxaldehyde in 70 mL of THF were added dropwise while maintaining an internal temperature between -5° C and 0° C. After 30 minutes at about -5° C, approximately 13% of the phosphonate ester still remained unreacted. Another 6.7 g (28 mmol) of the aldehyde was then added in THF at 0° C. After another 20 minutes, 4 to 5% of the phosphonate ester remained. An additional 0.27 g (1.12 mmols) of the aldehyde were added. After 30 minutes, the reaction was quenched with water and extracted with ethylacetate. The organic layer was dried over MgSθ4, filtered, and concentrated under reduced pressure to yield the crude product, 28.
EXAMPLE 25
Preparation of 29
107.6 mL (893 mmol) of 4-bromo-l,2-(methylenedioxy)- benzene were dissolved in 2L THF and cooled to -78° C. 357 mL (893 mmol) of nBuLi (2.5 M in hexanes) were then added dropwise while maintaining an internal temperature below -72° C. 202 g (425 mmol) of the product from Example 24 in 300 mL THF were added dropwise while maintaining an internal temperature below -70° C. After 30 minutes, the reaction was quenched with methanol at -70° C and allowed to warm to -10° C. Saturated aqueous NaHCθ3 was added and the phases separated. The aqueous layer was filtered through celite and extracted with ethylacetate. The ethylacetate layer was then dried over MgSθ4, filtered, and concentrated under reduced pressure to afford 320 g of the crude product, 29.
IH NMR δ (ppm) 0.92 (3H, t); 1.35 (2H,m); 1.68 (2H,m); 2.46 (3H,s); 2.75 (2H,m); centered at 3.05 (2H,dd,dd); centered at 3.4 (2H,dd,dd); 3.34 (3H,s); 3.96 (lH,m); 4.87 (IH, t); 5.18 (lH,d); 5.92 (2H,s); 6.71- 6.79 (3H, aromatic multiplet); 6.81-6.88 (2H, aromatic multiplet); 7.09- 7.18 (3H, aromatic multiplet), 7.64 (lH,d).
EXAMPLE 26
Preparation of 30
To a solution of 47.6 g (79.6 mmol) of 29, the product from Example 25 in 200 mL of isopropanol was added 44 mL of concentrated H2SO4 (18 M). The mixture was then heated to reflux. After 2.5 hours, the mixture was cooled to room temperature and diluted with water. The mixture was then extracted with ethylacetate and washed with a saturated aqueous solution of NaHCθ3. The organic phase was concentrated under reduced pressure and the residue dissolved in tert-buytl methyl ether. The ethereal solution was washed with IN aqueous HCl and with a saturated aqueous solution of NaHCθ3. The organic layer was then dried over MgSθ4, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography using a solvent gradient of 10: 1 hexane/ethylacetate to 5: 1 hexane/ethylacetate to afford 25.15 g (70%) of product, 30.
Η NMR δ( ppm) 0.91 ( 3H, triplet ); 1.07 (3H, d); 1.13 (3H,d); 1.35 (2H, m); 1.65 (2H,m); 2.71 (2H,m); 2.93 (2H,m); 4.7-4.96 (2H, overlapping multiplets); 5.96 (2H,s); 6.72 (3H, aromatic multiplet); 7.05 (lH,d), 7.43 (lH,d).
EXAMPLE 27
Preparation of 31
To a solution of 2 g (3.9 mmol) of 30, the product from Example 26, 66 mg (0.12 mmol) of DPPF (1 ,1 '- bis(diphenylphosphino)-ferrocene) and 67 mg (8 mmol) of NaHCθ3 in 20 mL of methanol was added 27 mg (0.12 mmol) of palladium diacetate. The mixture was heated at 70° C under 40 psi of carbon monoxide for 12 hours. The mixture was then cooled, concentrated under reduced pressure, and partitioned between ethylacetate and water. The aqueous layer was extracted with ethylacetate and the combined organic layers were dried over MgS04. The organic solvent was removed under reduced pressure to afford 1.56 g (94%) of the crude product, 31.
Η NMR δ (CDC13, ppm): 0.9(3H,t); 1.06(6H,d); 1.37(2H,m); 1.66(2H,m); 2.78(2H,m); 2.93(2H,m); 3.94(3H,s); 4.89(lH,m); 5.13(lH,t); 5.88(2H,s); 6.67-6.75(3H, aromatic multiplet); 7.2(lH,d); 7.56(lH,d). EXAMPLE 28
32
Preparation of 32
To a cold solution of 22 (see Example 22, MW 349.27, 1.3 equ, 63.76 g) in THF (450 ml) was added n-BuLi (1.7M in hexane, 1.3 equ, 110 ml), maintaining temperature below -70°C, and the mixture was stirred at -78°C for 10 min. The mixture was added to a solution of 31 (MW 427.50, 0.14 mol, 60.0 g) in THF (450 ml) through cannula below -70°C. The mixture was stirred at -78°C for 30 min, quenched with water (450 ml), and extracted with ethyl acetate (900 ml). The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water then brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo. 32 (MW 665.82) was isolated in 84% yield (78.4 g) by silica gel chromatography (heptane- ethyl acetate / gradient). iH NMR (CDC13): 0.87 (t, J=7.26, 3H), 1.04 (d, J=6.93, 3H), 1.05 (d, J=6.27,6H), 1.26 (m, 2H), 1.62 (m, 2H), 2.29 (m, IH), 2.71 (t, J=7.59, 2H), 2.92 (J=6.26, 2H), 3.03 (m, 2H), 3.45 (m, 2H), 3.80 (s, 3H), 4.52 (s, 2H), 4.66 (t, J=7.26, IH), 4.85 (m, IH), 5.82 (m, 2H), 6.56 (m, 4H), 6.7δ (s, IH), 7.02 (d, J=8.91 , IH), 7.14 (d, J=8.25, IH), 7.35 (m, 5H), 7.56 (d, J=8.25, IH).
EXAMPLE 29
Preparation of 33
To a solution of 32 (MW 665.82, 1 10 mmol, 73.06 g) in THF (750 ml) was added sodium tert-pentoxide (MW 110.14, 3 equ, 36.35g) at -40°C. The mixture was allowed to warm to 0°C, stirred at 0°C for 1.5 h, poured into water (1 L), and extracted with ethyl acetate (1 L). The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water then brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo. 33 (MW 665.82) was isolated in 66% yield (48.1 g) by silica gel chromatography (heptane- ethyl acetate / gradient). iH NMR (CDC13, ppm): 0.80 (d, J=5.94, 3H), 0.87 (t, J=7.26, 3H), 1.03 (d, J=6.27, 3H), 1.13 (d, J=6.27, 3H), 1.30 (m, 2H), 1.60 (m, 2H), 2.14 (m, 2H), 2.27 (m, IH), 2.71 (m, 2H), 3.08 (m, 2H), 3.37 (s, IH), 3.48 (d, J=8.91, IH), 3.80 (s, 3H), 4.37 and 4,44 (ABq, J=11.5, 2H), 4.91 (d, J=8.91, IH), 4.99 (m, IH), 5.92 (s, 2H), 6.65 (d, J=7.92, IH), 6.76 (m, 4H), 7,05 (d, J=7.92, IH), 7.28 (m, 6H), 7.71 (d, J=8.54, IH). EXAMPLE 30
33 34
Method A: Preparation of 34
To a predegassed solution of 33 (MW 665.82, 22.8 mmol, 15.2 g) and isopropyl alcohol (5 equ, 8.7 ml) in THF (100 ml) was added Sml2 (0.1 M in THF, 4.8 equ, 1.1 L) under argon atmosphere at room temperature. The mixture was stirred at the same temperature over night, concentrated in vacuo, poured into 0.5N HCl (250 ml), and extracted with ethyl acetate (250 ml). The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water, sat. aqueous NaHCθ3, 5% Na2Sθ3, water then brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo. 34 (MW 649.83) was isolated in quantitative yield (15.1 g) by silica gel chromatography (heptane- ethyl acetate / gradient). iH NMR (CDC13, ppm): 0.84 (t, J=7.26, 3H), 1.04 (d, J=6.93, 3H), 1.08 (d, J=6.27, 3H), 1.11 (d, J=6.27, 3H), 1.26 (m, 2H), 1.56 (m, 2H), 2.20 (m, IH), 2.65 (m, 2H), 2.72 (m, 2H), 3.18 (t, J=9.74, IH), 3.38 (m, 2H), 3.75 (s, 3H), 4.48 (d, J=8.90 IH), 4.49 (s, 2H), 4.96 (m, 2H), 5.95 (s, 2H), 6.73 (m, 5H), 6.91 (d, J=7.91, IH), 7.15 (d, J=7.92, IH), 7.30 (m, 6H). EXAMPLE 31
34 35
Preparation of 35
To a solution of 34 (MW 649.83, 18.5 mmol, 12.0 g) in THF (60 ml) and isopropyl alcohol (60 ml) was added 10% Pd-C (10.5 g), and the mixture was hydrogenated under H2 (3.5 kg/cm2) at 60°C for 4 h. The catalyst was removed by filtration, and the filtrate was evaporated in vacuo to give 35 (MW 559.70) in 83% yield (8.62 g). iH NMR (CDC 13, ppm): 0.86 (t, J=7,26, 3H), 1.01 (d, J=6.60, 3H), 1.10 (d, J=6.27, 3H), 1.13 (d, J=6.27, 3H), 1.26 (m, 2H), 1.56 (m, 2H), 2.13 (m, IH), 2.65 (m, 2H), 2.78 (m, 2H), 3.28 (t, J=9.73, IH), 3.50 (m, 2H), 3.78 (s, 3H), 4.51 (d, J=9.57, IH), 4.98 (m, IH), 5.04 (d, J=10.2, IH), 5.97 (s, 2H), 6.73 (m, 5H), 6,86 (d, J=8.25, IH), 6.95 (d, J=7.92, IH), 7.20 (d, J=7.92, IH). EXAMPLE 32
35 36
Preparation of 36 To a solution of 35 (NW 559.70, 15.4 mmol, 8.62 g) and
TEA (5.7 equ, 12.3 ml) in DMSO (25 ml) was added SO3-PY (MW 159.16, 2.9 equ, 7.05 g) at room temperature. The mixture was stirred for 15 min, poured into water (1 L), and extracted with ethyl acetate (200 ml x 3 times). The combined organic layers were washed with 10% citric acid then brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo to give 9.6 g of crude aldehyde.
To a solution of the crude aldehyde and 2-methyl-2-butene (30 ml) in ferfbutanol (60 ml) was added a solution of NaCI02 (22.1 mmol, 2.00 g) in 0.5M (I)H 3.3) KH2PO4-H3PO4 buffer (60 ml) at room temperature. The mixture was stirred for 45 min and extracted with ethyl acetate (200 ml). The organic layer was washed with 10% citric acid, water then brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo to give crude mono carboxyiic acid.
To a solution of the crude mono carboxyiic acid in methanol (40 ml) and dioxane (20 ml) was added 4N NaOH (148 mmol, 37 ml), and the mixture was stirred at 60°C for 1 h. After cooling, the mixture was diluted with water (50 ml), adjusted to pH 8 with 6N HCl, and washed with ethyl acetate (100 ml). The aqueous layer was acidified to pH 3 with HCl aq, and extracted with ethyl acetate (100 ml x 3 times). The combined organic layers were washed with water then brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo. 36 (MW 531.60) was isolated in 48% yield (3.90 g) by silica gel chromatography (CH2θ2-ethyl acetate / gradient). H NMR (CDC 13, ppm): 0.84 (t, J=7.26, 3H), 1.26 (m, 2H), 1.32 (d, J=6.60, 3H),1.49 (m, 2H), 2.67 (m, 3H), 3.14 (m, 2H), 3.59 (t, J=9.57, IH), 3.75 (s, 3H), 4.58 (d, J=9.57, IH), 4.99 (d, J=9.56, IH), 6.00 (s, 2H), 6.70 (d, J=2.97, IH), 6.78 (s, IH), 6.83 (m, 3H), 6.94 (d, J=8.90, IH), 7.06 (d, J=7.91, IH), 7.33 (d, J=7.91 , IH).
EXAMPLE 33
37 Preparation of 37
To a solution of 2.62 g (7.02 mmol) of the arylbromide 17, Example 17 in 15 mL THF was added 3.3 mL (7.1 mmol) of nBuLi (2.15 M in hexanes) while maintaining an internal temperature below -70° C. After 10 minutes, the solution was transferred via cooled cannula (dry ice) to a solution of the diester, 31 produced in Example 27 in 35 mL of THF. The solution was observed to turn a green-black color. The mixture was stirred for an additional 0.5 hours and then quenched with aqueous NaHCθ3. The aqueous layer was extracted with ethylacetate (2X) and the combined organic layers dried over MgSθ4. Column chromatography using a 6: 1 hexane/ethylacetate solvent system afforded 2.0 g (62%) of product 37 as a yellow oil. IH NMR δ (CDC13, ppm): 0.08(6H,s); 0.88(3H,t); 0.92(9H,s); 0.98(3H,d); 1.05(6H,d); 1.32(2H,m); 1.62(2H,m); 2.11 (lH,dd); 2.72(2H,m); 2.93(2H,m); 3.12(lH,dd); 3.51(lH,dd); 3.62(lH,dd); 3.83(3H,s); 4.66(lH,t); 4.δ7(lH,m); 5.82(2H,m); 6.5-6.63(4H, aromatic multiplets); 6.81(lH,m); 7.02(lH,d); 7.13(lH,d); 7.58(lH,d).
EXAMPLE 34
37 38
Preparation of 38 To a solution of 0.8 g (1.16 mmol) of the silyl ether, 37 from Example 33 in 20 mL acetonitrile at room temperature was added 0.5 mL og aqueous HF. After 10 minutes, the reaction was quenched with aqueous NaHC03 and extracted with ethylacetate (2X). The organic layer was dried over MgSθ4, filtered, and concentrated under reduced pressure to afford 0.66 g (99%) of the desilylated product, 38 as a yellow foam.
IH NMR (CDC13, ppm, 300 MHz): δ 0.8 (t, 3H), 0.95 (d, 3H), 1.00 (m, 6H), 1.25 (m, 3H), 1.55 (m, 2H), 2.00 (m, I H), 2.77 (m, 3H), 2.90 (m, IH), 3.16 (m, IH), 3.40 (m, 2H), 3.75 (s, 3H), 4.55 (t, I H), 4.81 (m, IH), 5.76 (m, 2H), 6.50 (m, 4H), 6.74 (bs, IH), 6.89 (d, IH), 7.43 (d, IH), 7.85 (d, IH).
EXAMPLE 35
Preparation of 39
0.21 g (0.37 mmol) of compound 38, from Example 34 were dissolved in 5 mL THF and cooled to -10° C. 0.12 g (1.1 mmol) of sodium t-pentoxide were then added as a solid and the reaction allowed to warm to room temperature. The reaction was subsequently quenched with IN aqueous HCl and extracted with ethyl acetate (2X). The organic layer was dried over MgS04, filtered, and concentrated under reduced pressure to afford 0.21 g (100%) of the crude cyclized product, 39. iH NMR δ (CDCI3, ppm, 300 MHz): 0.8 (m, 2H), 0.89 (t, 3H), 1.03 (d, 3H), 1.17 (m, 6H), 1.32 (m, 2H), 1.61 (m, 2H), 2.1 1 (m, IH), 2.29 (m, IH), 2.82 (m, 2H), 3.15 (m, IH), 3.30 (m, IH), 3.49 (d, IH), 3.78 (t, 3H), 5.1 1 (m, 2H), 5.93 (s, 2H), 6.78 (m, 6H), 7.25 (d, IH), 7.58 (d, IH).
EXAMPLE 36
Preparation of 40
To a solution of dihydroxy ester (4.2 g), 39 in acetone (20 ml) at -15 °C was added Jones reagent (8.4 ml) over a period of lh. The reaction was aged 0.5 h, warmed to 0 °C and quenched with water. The phases were separated and the aqueous phase was extracted with MTBE (2x10 ml). The organic phase was concentrated to a tan solid and the crude material was carried directly to the deoxygenation reaction. iH NMR δ (CDCI3, ppm, 300 MHz): 0.85 (t, 3H), 1.08 (m, 9H), 1.39 (m, 2H), 1.52 (m, 2H), 2.54 (m, IH), 2.69 (m, 2H), 3.65 (m, 2H), 3.73 (s, 3H), 4.83 (m, IH), 5.02 (m, IH), 5.97 (s, 2H), 6.75 (m, 6H), 7.10 (d, IH), 7.43 (d, IH).
EXAMPLE 37
OMe
41
Preparation of 41
To a solution of 1.0 g (1.7 mmol) of compound 40, from Example 36 in 10 mL of tetrahydrofuran (THF) was added 51 mL (5.1 mmol) of Sml2 (0.1 M in THF) at room temperature. After 15 minutes, the reaction was quenched with IN aqueous HCl and extracted with ethyl acetate twice. The organic layers were dried over MgSθ4, filtered and concentrated under reduced pressure to afford 0.98 g (100%) of the crude product 41 as a single diastereomer by iH NMR. !H NMR δ (CDC13, ppm, 300 MHz): 0.85 (t, 3H), 1.05 (d, 3H), 1.13 (m, 2H), 1.15 (d, 3H), 1.3 (d, 3H), 1.5 (m, 2H), 2.65 (m, 2H), 2.95 (m, 2H), 3.35 (dd, IH), 3.52 (t, IH), 3.72 (t, 3H), 4.55 (d, IH), 5.00 (d, IH), 5.90 (s, 2H), 6.75 (m, 5H), 6.95 (d, IH), 7.08 (d, IH), 7.37 (d, IH).

Claims

WHAT IS CLAIMED IS:
1. A compound of Formula I:
wherein
represents:
a) 5- or 6-membered heterocyclyl containing one, two or three double bonds, but at least one double bond and 1 , 2 or 3 heteroatoms selected from O, N and S, the heterocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, C02R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-Cδ alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, b) 5- or 6-membered carbocyclyl containing one or two double bonds, but at least one double bond, the carbocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-Cδ alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, c) aryl, wherein aryl is as defined below,
Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-Cδ alkynyl, or C3-C8 cycloalkyl, are unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, C02R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, C3-Cδ cycloalkyl, CO(CH2)nCH3, and aryl is defined as phenyl or naphthyl, which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, Cl -Cδ alkyl, C2-Cδ alkenyl, C2-Cδ alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, CO(CH2)nCH2N(R5)2, and when two substituents are located on adjacent carbons they can join to form a 5- or 6- membered ring with one, two or three heteroatoms selected from O, N, and S, which is unsubstituted or substituted with with one, two or three substituents selected from the group consisting of: H, OH, CO2R6, Br, Cl, F, I, CF3, N(R7)2, Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, and
n is 0 to 5;
Rl is: a) C l -Cδ alkyl, C2-Cδ alkenyl, C2-Cδ alkynyl, C3-Cδ cycloalkyl, b) aryl, or c) heteroaryl;
heteroaryl is defined as a 5- or 6-membered aromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S , which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cs alkoxy, Cl-Cδ alkyl, C2-C8 alkenyl, C2-C alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, a) Cl-Cδ alkyl, b) aryl, or c) heteroaryl;
R4 is Cl-Cδ alkyl; and
R5 is: H, Cl-Cδ alkyl, or aryl.
2. A process for the preparation of a compound of formula I:
wherein
represents:
a) 5- or 6-membered heterocyclyl containing one, two or three double bonds, but at least one double bond and 1, 2 or 3 heteroatoms selected from O, N and S, the heterocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-C alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, b) 5- or 6-membered carbocyclyl containing one or two double bonds, but at least one double bond, the carbocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl -Cs alkoxy, Cl -Cδ alkyl, C2-C alkenyl, C2-C alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and CO(CH2)ΠCH2N(R5)2, c) aryl, wherein aryl is as defined below,
Cl -Cδ alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-Cδ alkynyl, or C3-Cδ cycloalkyl, are unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4 Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, C3-Cδ cycloalkyl, CO(CH2)nCH3, and aryl is defined as phenyl or naphthyl, which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-Cδ alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, CO(CH2)nCH2N(R5)2, and when two substituents are located on adjacent carbons they can join to form a 5- or 6- membered ring with one, two or three heteroatoms selected from O, N, and S, which is unsubstituted or substituted with with one, two or three substituents selected from the group consisting of: H, OH, CO2R6, Br, Cl, F, I, CF3, N(R7)2,
Cl-Cδ alkoxy, C1-C8 alkyl, C2-C8 alkenyl, C2-Cδ alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and
n is 0 to 5; Rl is: a) Cl-Cδ alkyl, C2-Cδ alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, b) aryl, or c) heteroaryl;
heteroaryl is defined as a 5- or 6-membered aromatic ring containing 1 , 2 or 3 heteroatoms selected from O, N and S , which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy, Cl -Cδ alkyl, C2-Cδ alkenyl, C2-C alkynyl, or C3-C cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2,
R3a is: a) -CO-Cl-Cδ alkyl, b) -CO-aryl, or c) -CO-heteroaryl;
R3b is: a) C1-C8 alkyl, b) aryl, or c) heteroaryl;
R4 is Cl-C8 alkyl; and
R5 is: H, Cl-Cδ alkyl, or aryl,
comprising reacting a
in the presence of a strong base and an aprotic solvent at a temperature range of -78°C to about 25°C.
3. The process as recited in Claim 2, wherein the strong base is selected from the group consisting of: LDA, LiHMDS, KHMDS, NaHMDS, KOtøu, and sodium t-amylate.
4. The process as recited in Claim 3, wherein the aprotic solvent is selected from the group consisting of tetrahydrofuran, diethyl ether, methyl t-butyl ether, benzene, toluene, pentane, hexane, dioxane and a mixture of said solvents.
5. The process as recited in Claim 4, wherein the temperature range is about -50°C to about 25 °C.
6. The process as recited in Claim 5, wherein the strong base is LiHMDS, KHMDS, or NaHMDS, the aprotic solvent is tetrahydrofuran and the temperature range is about -0°C to about 25°C.
A process for the preparation of a compound of formula II:
wherein
represents: a) 5- or 6-membered heterocyclyl containing one, two or three double bonds, but at least one double bond and 1 , 2 or 3 heteroatoms selected from O, N and S, the heterocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH,
CO2R4, Br, Cl, F, I, CF3, N(R5)2, C1-C8 alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-C alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, b) 5- or 6-membered carbocyclyl containing one or two double bonds, but at least one double bond, the carbocyclyl is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, C1-C8 alkoxy, C1-C8 alkyl, C2-C alkenyl, C2-C alkynyl, or C3-C8 cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2, c) aryl, wherein aryl is as defined below,
Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-C8 alkenyl, C2-Cδ alkynyl, or
C3-Cδ cycloalkyl, are unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3, N(R5)2, Cl-Cδ alkoxy,
C3-Cδ cycloalkyl, CO(CH2)nCH3, and aryl is defined as phenyl or naphthyl, which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH, CO2R4, Br, Cl, F, I, CF3,
N(R5)2, Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-C8 alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, CO(CH2)nCH2N(R5)2, and when two substituents are located on adjacent carbons they can join to form a 5- or 6- membered ring with one, two or three heteroatoms selected from O, N, and S, which is unsubstituted or substituted with with one, two or three substituents selected from the group consisting of: H, OH, CO2R6, Br, Cl, F, I, CF3, N
(R7)2, Cl-Cδ alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-Cδ alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and
n is 0 to 5;
Rl is: a) C 1 -Cδ alkyl, C2-Cδ alkenyl, C2-Cδ alkynyl, C3-Cδ cycloalkyl, b) aryl, or c) heteroaryl;
heteroaryl is defined as a 5- or 6-membered aromatic ring containing 1 , 2 or 3 heteroatoms selected from O, N and S , which is unsubstituted or substituted with one, two or three substituents selected from the group consisting of: OH,
CO2R4, Br, Cl, F, I, CF3, N(R , Cl -Cδ alkoxy, Cl-Cδ alkyl, C2-Cδ alkenyl, C2-Cδ alkynyl, or C3-Cδ cycloalkyl, CO(CH2)nCH3, and CO(CH2)nCH2N(R5)2,
a) Cl-Cδ alkyl, b) aryl, or c) heteroaryl;
R4 is Cl-Cδ alkyl; and
R5 is: H, Cl-Cδ alkyl, or aryl,
comprising reacting a compound of formula I
with a reducing agent and optionally an acid in a solvent at a temperature range of about -78°C to about 100°C.
8. The process as recited in Claim 7, wherein the reducing agent is selected from the group consisting of: a hydride, a borane, a C5-C6 cycloalkene with a transition metal catalyst, H2 with a transition metal catalyst and Sml2-
9. The process as recited in Claim 8, wherein the acid is a Lewis acid, when the reducing agent is a hydride, a borane or a C5-C6 cycloalkene with a transition metal catalyst; a protic acid, when the reducing agent is H2 with a transition metal catalyst; or is absent when the reducing agent is Sml2.
10. The process as recited in Claim 9, wherein the solvent is an aprotic solvent, when the acid is a Lewis acid and the reducing agent is a hydride, a borane or a C5-C6 cycloalkene with a transition metal catalyst; a protic solvent, when the acid is a protic acid and the reducing agent is H2 with a transition metal catalyst; or a solvent system consisting a protic solvent in combination with aprotic solvent.
11. The process as recited in Claim 10, wherein the temperature range is about -78°C to about 20°C, when the acid is a Lewis acid and the reducing agent is a hydride or a borane.
12. The process as recited in Claim 10, wherein the temperature range is about 0°C to 100°C, when the acid is a Lewis acid or a protic acid and the reducing agent is a C5-C6 cycloalkene with a transition metal catalyst or H2 with a transition metal catalyst.
13. The process as recited in Claim 10, wherein the temperature range is about 0°C to 30°C, when the reducing agent is
Sml2.
14. The process as recited in Claim 11, wherein the aprotic solvent selected from the group consisting of: tetrahydrofuran, diethyl ether, methyl t-butyl ether, dioxane, CH2CI2, CHCI3, nitromethane, toluene, and dichlorobenzene.
15. The process as recited in Claim 12, wherein the protic solvent selected from the group consisting of: ethanol, methanol, and isopropanol.
16. The process as recited in Claim 13, wherein the solvent system consists of a protic solvent selected from the group consisting of methanol, ethanol or isopropanol and an aprotic solvent selected from the group consisting of: tetrahydrofuran, diethyl ether, methyl t-butyl ether or dioxane.
17. The process as recited in Claim 13, wherein the Lewis acid is selected from the group consisting of: ΗCI4, BF3, BCI3, SnCl4, AICI3, and TiCl2(OiPr)2.
18. The process as recited in Claim 15, wherein the temperature range is about -20°C to about 10°C, when the reducing agent is a hydride or a borane.
19. The process as recited in Claim 13, wherein the protic acid is selected from the group consisting of: trifluoroacetic acid, HCl, and H2SO4.
20. The process as recited in Claim 16, wherein the hydride is selected from the group consisting of: R3SiH, R2SiH2, wherein R is Cl-C8 alkyl or aryl, and NaBH4.
21. The process as recited in Claim 16, wherein the borane is selected from the group consisting of: BH3βNHMe2, BH3-SMe2, BH3»pyridine, and BH3-THF.
22. The process as recited in Claim 15, wherein the reducing agent is a C5-C6 cycloalkene with a transition metal catalyst selected from cyclohexene or cyclohexadiene with Pd/C, Pt-C, Rh Al or Raney Ni.
23. The process as recited in Claim 20, wherein the temperature range is about 0°C to about 40°C.
24. The process as recited in Claim 18, wherein the H2/transition metal catalyst is selected from the group consisting of: Pd-C, Pt-C, Rh/Al and Raney Ni.
25. The process as recited in Claim 22, wherein the temperature range is about 0°C to about 40°C.
26. The process as recited in Claim 18, wherein the hydride is R3SiH, the Lewis acid is TiCl4 the aprotic solvent is nitromethane and the temperature range is about -5°C to about 5°C.
27. A process for the preparation of a compound of formula:
comprising reacting a ketone of formula:
OMe in tetrahydrofuran with about 3 to about 5 equivalents of lithium bis(trimethylsilyl)amide at about -50°C to about 25°C.
28. A process for the preparation of a compound of formula:
comprising reacting the tertiary alcohol
in nitromethane with Et3SiH and TiCH at about -5°C to about 5°C.
29. A process for the preparation of a compound of formula:
comprising reacting the tertiary alcohol
in a solution of isopropyl alcohol and tetrahydrofuran with Sml2 at about 10° - 30°C.
30. A process for the preparation of a compound of formula:
comprising reacting the tertiary alcohol
in a solution of isopropyl alcohol and tetrahydrofuran with Sml2 at about 10° - 30°C.
EP97937187A 1996-08-09 1997-08-08 Stereoselective deoxygenation reaction Withdrawn EP0923557A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US2361496P 1996-08-09 1996-08-09
US23614P 1996-08-09
GBGB9617900.7A GB9617900D0 (en) 1996-08-28 1996-08-28 Stereoselective deoxygenation reaction
GB9617900 1996-08-28
US2843896P 1996-10-10 1996-10-10
US28438P 1996-10-10
GBGB9625806.6A GB9625806D0 (en) 1996-12-12 1996-12-12 Stereoselective deoxygenation reaction
GB9625806 1996-12-12
PCT/US1997/014045 WO1998006700A1 (en) 1996-08-09 1997-08-08 Stereoselective deoxygenation reaction

Publications (2)

Publication Number Publication Date
EP0923557A1 true EP0923557A1 (en) 1999-06-23
EP0923557A4 EP0923557A4 (en) 1999-12-08

Family

ID=27451511

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97937187A Withdrawn EP0923557A4 (en) 1996-08-09 1997-08-08 Stereoselective deoxygenation reaction

Country Status (5)

Country Link
EP (1) EP0923557A4 (en)
JP (1) JPH11514676A (en)
AU (1) AU711936B2 (en)
CA (1) CA2262676A1 (en)
WO (1) WO1998006700A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3262805B2 (en) * 1996-08-09 2002-03-04 メルク エンド カンパニー インコーポレーテッド Asymmetric conjugate addition reaction
US6172235B1 (en) 1996-08-09 2001-01-09 Merck & Co., Inc. Asymmetric conjugate addition reaction
WO1999037639A1 (en) * 1998-01-21 1999-07-29 Banyu Pharmaceutical Co., Ltd. Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative
WO1999052851A1 (en) * 1998-04-09 1999-10-21 Merck & Co., Inc. Phosphate-mediated cyclization
US6031101A (en) * 1998-04-09 2000-02-29 Merck & Co., Inc. Oxidation process using tempo
US6046327A (en) * 1998-04-09 2000-04-04 Merck & Co., Inc. Phosphate-mediated cyclization
JP2002511465A (en) * 1998-04-09 2002-04-16 メルク エンド カムパニー インコーポレーテッド Oxidation method using TEMPO
CA2327926A1 (en) * 1998-04-09 1999-10-21 Merck & Co., Inc. Oxidation process using periodic acid
AR029289A1 (en) * 2000-07-05 2003-06-18 Ishihara Sangyo Kaisha DERIVED FROM BENZOILPIRIDINE OR ITS SALT, FUNGICIDE THAT CONTAINS IT AS AN ACTIVE INGREDIENT, ITS PRODUCTION AND INTERMEDIARY PROCESS TO PRODUCE IT
JP4608140B2 (en) * 2000-07-05 2011-01-05 石原産業株式会社 Benzoylpyridine derivatives or salts thereof, fungicides containing them as active ingredients, methods for producing them, and intermediates for producing them
AP1286A (en) * 2000-07-05 2004-06-26 Ishihara Sangyo Kaisha Benzoylpyridine derivative or its salt, Fungicide containing it as an active ingredient, its production process and intermediate for producing it.
MXPA02012739A (en) 2001-03-09 2004-04-20 Nugen Technologies Inc Methods and compositions for amplification of rna sequences.
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
AU2007240437B2 (en) 2006-04-20 2012-12-06 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
JP5331680B2 (en) 2006-04-20 2013-10-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Inhibitors of c-fms kinase
JO3240B1 (en) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv Inhibitors of c-fms Kinase
CN102131772B (en) 2008-07-30 2015-03-11 英特威国际有限公司 Process for preparing oxazoline-protected aminodiol compounds useful as intermediates to florfenicol
JOP20180012A1 (en) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv Sulfonylation process using nonafluorobutanesulfonyl fluoride
AU2013299922B2 (en) 2012-08-07 2018-06-21 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008799A1 (en) * 1991-11-05 1993-05-13 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1997017342A1 (en) * 1995-11-08 1997-05-15 Smithkline Beecham Corporation A process of making 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives
WO1997037665A1 (en) * 1996-04-04 1997-10-16 Banyu Pharmaceutical Co., Ltd. Method of treating heart failure with endothelin antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (en) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity
CN1049219C (en) * 1993-08-18 2000-02-09 万有制药株式会社 Fused heteroaromatic cyclopentene derivative having endothelin-antagonist activity
US5389620A (en) * 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008799A1 (en) * 1991-11-05 1993-05-13 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1997017342A1 (en) * 1995-11-08 1997-05-15 Smithkline Beecham Corporation A process of making 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives
WO1997037665A1 (en) * 1996-04-04 1997-10-16 Banyu Pharmaceutical Co., Ltd. Method of treating heart failure with endothelin antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9806700A1 *

Also Published As

Publication number Publication date
WO1998006700A1 (en) 1998-02-19
AU711936B2 (en) 1999-10-28
JPH11514676A (en) 1999-12-14
AU3975797A (en) 1998-03-06
CA2262676A1 (en) 1998-02-19
EP0923557A4 (en) 1999-12-08

Similar Documents

Publication Publication Date Title
EP0923557A1 (en) Stereoselective deoxygenation reaction
AU728441B2 (en) Endothelin intermediates by asymmetric conjugate addition reaction using a chiral additive
US5962688A (en) Stereoselective deoxygenation reaction
WO1999007367A1 (en) Asymmetric conjugate addition reaction
US6353110B1 (en) Asymmetric conjugate addition reaction
US6172231B1 (en) Oxidation process using periodic acid
CA2262837C (en) An asymmetric conjugate addition reaction
US5849914A (en) Compounds formed by an asymmetric conjugate addition reaction
US6172235B1 (en) Asymmetric conjugate addition reaction
US5998625A (en) Asymmetric conjugate addition reaction using a chiral additive
EP1070041B1 (en) Phosphate-mediated cyclization
US6046327A (en) Phosphate-mediated cyclization
AU748208B2 (en) Oxidation process using tempo
MXPA99006544A (en) Endothelin intermediates by asymmetric conjugate addition reaction using a chiral additive
WO1999052899A1 (en) Oxidation process using periodic acid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990309

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991025

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 6C 07D 221/02 A, 6C 07D 471/00 B, 6A 61K 31/335 B, 6A 61K 31/435 B, 6C 07D 405/04 B

17Q First examination report despatched

Effective date: 20001019

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020403

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1018259

Country of ref document: HK